Document:

Exhibit

SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 

THIS SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT ("Amendment"), dated effective as of August 26, 2015 (the “Effective Date”), is made and entered into by and among THERMON INDUSTRIES, INC., a Texas corporation (the “US Borrower”), Thermon Canada Inc., a Nova Scotia company (the “Canadian Borrower” and, together with the US Borrower, the “Borrowers” and each individually, a “Borrower”), the other undersigned Credit Parties (as defined in the Credit Agreement), JPMORGAN CHASE BANK, N.A., a national banking association, as US Agent, US Swingline Lender, a US L/C Issuer and a US Lender (as each is defined in the Credit Agreement), JPMORGAN CHASE BANK, N.A., TORONTO BRANCH, as Canadian Agent, Canadian Swingline Lender, a Canadian L/C Issuer and a Canadian Lender (as each is defined in the Credit Agreement), and all other undersigned Lenders (as defined in the Credit Agreement).

RECITALS:

WHEREAS, all of the undersigned are parties to an Amended and Restated Credit Agreement dated as of April 19, 2013, as previously amended pursuant to the terms of that certain First Amendment of Amended and Restated Credit Agreement dated as of June 11, 2014, by and among all of the undersigned (collectively the "Credit Agreement"); and

WHEREAS, all of the undersigned have agreed, on the terms and conditions herein set forth in this Amendment, that the Credit Agreement be further amended in certain respects.

AGREEMENTS:

NOW, THEREFORE, in consideration of the premises and the mutual agreements, representations and warranties herein set forth, and for other good and valuable consideration, the receipt and sufficiency which are hereby acknowledged and confessed, all of the undersigned do hereby agree as follows:

Section 1.   General Definitions.  Capitalized terms used herein which are defined in the Credit Agreement shall have the same meanings when used herein.

Section 2.    Replacement of Certain Lenders; Corresponding Increases of Revolving Loan Commitments and Outstanding Principal Amount of US Term Loans by Remaining Lenders; Corresponding Amendments of Required Canadian Lenders, Required Lenders, Required US Revolving Lenders and Required US Term Lenders Definitions.  

(a)    Replacement of Certain Lenders.  Pursuant to the terms of certain Assignments dated as of the Effective Date (collectively the “Replaced Lender Assignments”), (i) Compass Bank and Comerica Bank (collectively the “Replaced Lenders”) have each sold and assigned all of its respective rights and obligations in its capacity as a Lender under the Credit Agreement (including the Loans owing to such Replacement Lender) and the other Loan Documents to the applicable undersigned Lenders, in the respective applicable percentages and amounts described in the Replaced Lender 

1

 AUS:0050100/03071:598895v13

Assignments for each applicable undersigned Lender, and (ii) each of the undersigned Lenders, to the extent applicable, has purchased and assumed from each applicable Replaced Lender, in the respective applicable percentages and amounts described in the Replaced Lender Assignments for such undersigned Lender, the respective rights and obligations of the applicable Replaced Lender in its capacity as a Lender under the Credit Agreement (including the Loans owing to such Replacement Lender) and the other Loan Documents. As a result, it is hereby acknowledged that the Replaced Lenders are no longer Lenders under the Credit Agreement.

(b)    Resulting Increases of Revolving Loan Commitments.   In order to comprehensively reflect the corresponding cumulative increases in each undersigned Lender’s applicable US Revolving Loan Commitment and/or Canadian Loan Commitment evidenced by the Replaced Lender Assignments, Schedule 1.1(b) to the Credit Agreement is hereby replaced in its entirety with Schedule 1.1(b) attached to this Amendment.  Accordingly, (i) each undersigned US Revolving Lender’s respective US Revolving Loan Commitment is hereby agreed to be the amount set forth opposite such US Revolving Lender’s name in the attached Schedule 1.1(b) under the heading “US Revolving Loan Commitments”, as the same may be reduced or increased from time to time in accordance with the terms of the Credit Agreement, and (ii) each undersigned Canadian Lender’s respective Canadian Revolving Loan Commitment is hereby amended to be the amount set forth opposite such Canadian Lender’s name in the attached Schedule 1.1(b) under the heading “Canadian Revolving Loan Commitments”, as the same may be reduced or increased from time to time in accordance with the terms of the Credit Agreement.  Each undersigned US Revolving Lender hereby severally agrees to fund to the US Agent, as of the Effective Date and in accordance with the other applicable provisions of the Credit Agreement, the pro rata amount of the US Revolving Loans of the Replaced Lenders outstanding on the Effective Date (if any) which have been purchased and assumed by such US Revolving Lender pursuant to the terms of the Replaced Lender Assignments, and the US Agent agrees to promptly pay the applicable portions thereof to the applicable Replaced Lenders promptly after receipt of such amount from such US Revolving Lender.  Each undersigned Canadian Lender hereby severally agrees to fund to the Canadian Agent, as of the Effective Date and in accordance with the other applicable provisions of the Credit Agreement, the pro rata amount of the Canadian Revolving Loans of the Replaced Lenders outstanding on the Effective Date (if any) which have been purchased and assumed by such Canadian Lender pursuant to the terms of the Replaced Lender Assignments, and the Canadian Agent agrees to promptly pay the applicable portions thereof to the applicable Replaced Lenders promptly after receipt of such amount from such Canadian Lender.

(c)    Resulting Increases of Outstanding Principal Amount of US Term Loans.   
In order to comprehensively reflect the corresponding cumulative increases in the outstanding principal amount of the US Term Loan of each undersigned US Term Lender evidenced by the Replaced Lender Assignments, the respective outstanding principal amount of each US Term Lender’s US Term Loan is hereby agreed to be the amount set forth opposite such US Term Lender’s name in Exhibit A attached hereto.  Each undersigned US Term Lender hereby severally agrees to fund to the US Agent, as of the Effective Date and in accordance with the other applicable provisions of the Credit Agreement, the amount of such US Term Lender’s respective increase in the outstanding principal amount of its US Term Loan, and the US Agent agrees to promptly pay the applicable portions thereof to the 

2

 AUS:0050100/03071:598895v13

applicable Replaced Lenders promptly after receipt of such amount from such US Term Lender.  

(d)    The definitions of “Required Canadian Lenders”, “Required Lenders”, “Required US Revolving Lenders” and “Required US Term Lenders” contained in Section 11.1 of the Credit Agreement are hereby amended and restated in their entirety to hereafter be and read as follows:

“Required Canadian Lenders” means at any time (a) not less than three (3) Canadian Lenders then holding more than fifty percent (50%) of the sum of the Aggregate Canadian Revolving Loan Commitments then in effect, or (b) if the Aggregate Canadian Revolving Loan Commitments have terminated, not less than three (3) Canadian Lenders then holding more than fifty percent (50%) of the sum of the US Dollar Equivalent of the aggregate outstanding amount of Canadian Revolving Loans, the US Dollar Equivalent of outstanding Canadian Letter of Credit Obligations, the US Dollar Equivalent of amounts of participations in Canadian Swing Loans and the US Dollar Equivalent of the principal amount of unparticipated portions of Canadian Swing Loans.
“Required Lenders” means at any time not less than three (3) Lenders then holding more than fifty percent (50%) of the sum of (a) the Aggregate US Revolving Loan Commitment then in effect, or if the Aggregate US Revolving Loan Commitment has terminated, the US Dollar Equivalent of the aggregate unpaid principal amount of Revolving Loans (other than Swing Loans) then outstanding, outstanding Letter of Credit Obligations, amounts of participations in Swing Loans and the principal amount of unparticipated portions of Swing Loans, and (b) the Aggregate US Term Loan Commitment then in effect, or if the US Term Loans have been advanced or if the Aggregate US Term Loan Commitment has otherwise terminated, the aggregate unpaid principal amount of the US Term Loans then outstanding.  
“Required US Revolving Lenders” means at any time (a) not less than three (3) US Revolving Lenders then holding more than fifty percent (50%) of the Aggregate US Revolving Loan Commitment then in effect, or (b) if the Aggregate US Revolving Loan Commitment has terminated, not less than three (3) US Revolving Lenders then holding more than fifty percent (50%) of the sum of the aggregate outstanding amount of US Revolving Loans, outstanding US Letter of Credit Obligations, amounts of participations in US Swing Loans and the principal amount of unparticipated portions of US Swing Loans.
“Required US Term Lenders” means at any time not less than three (3) US Term Lenders then holding more than fifty percent (50%) of the aggregate unpaid principal amount of the US Term Loans then outstanding. 
Section 3.     Modification of “Applicable Margin” Definition. The definition of “Applicable Margin” contained in Section 11.1 of the Credit Agreement is hereby amended and restated in its entirety to hereafter be and read as follows:

3

 AUS:0050100/03071:598895v13

“Applicable Margin” means, for any day, with respect to any LIBOR Rate Loan, CDOR Rate Loan, Base Rate Loan or Canadian Prime Rate Loan, or with respect to the Unused Commitment Fee, as the case may be, the applicable rate per annum set forth below under the caption “Adjusted LIBOR Rate Spread/CDOR Rate Spread”, “Base Rate Spread/Canadian Prime Rate Spread” or “Unused Commitment Fee Rate”, as the case may be, based upon the Leverage Ratio, provided that until the effective date of the first adjustment in the Applicable Margin occurring after August 26, 2015 in accordance with the terms set forth below, the “Applicable Margin” shall be the applicable rate per annum set forth below in Category 3.. 
	
				
	Leverage Ratio
	Adjusted LIBOR Rate Spread/CDOR Rate Spread/ Canadian Prime Rate Spread
	Base Rate Spread
	Unused Commitment  Fee Rate

	Category 1:
≥ 2.00 to 1.0

	

2.25%
	

1.25%
	

0.35%

	Category 2:
< 2.00 to 1.0, but
≥ 1.50 to 1.0

	

2.00%
	

1.00%
	

0.30%

	Category 3:
< 1.50 to 1.0, but
≥ 1.00 to 1.0

	

1.75%
	

0.75%
	

0.25%

	Category 4:
< 1.00 to 1.0

	

1.50%
	

0.50%
	

0.20%

For purposes of the foregoing, (a) the Applicable Margin shall be determined as of the end of each Fiscal Quarter (commencing with the Fiscal Quarter ending September 30, 2015) based upon the Leverage Ratio during the most recently ended Fiscal Quarter and (b) each change in the Applicable Margin shall be effective on and including the fifth (5th) Business Day after the date of delivery to the US Agent of the consolidated financial statements of Holdings indicating such change.  Notwithstanding the foregoing, the “Applicable Margin” shall be the applicable rate per annum set forth above in Category 1 during the period that any Specified Event of Default exists.
Section 4.    Modification of Permitted Acquisition Related Provisions.   

(a)    Deletion of Liquidity Requirement and Increase of Aggregate US Dollar Equivalent Limitation in “Permitted Acquisition” Definition.   

(i)    Subparagraph (e) in the definition of “Permitted Acquisition” contained in Section 11.1 of the Credit Agreement is hereby deleted in its entirety and replaced with the words “Reserved”.
 

4

 AUS:0050100/03071:598895v13

(ii)    Subparagraph (f) in the definition of “Permitted Acquisition” contained in Section 11.1 of the Credit Agreement is hereby amended and restated in its entirety to hereafter be and read as follows:

(f)    the total consideration paid or payable (including without limitation, all transaction costs, assumed Indebtedness and Liabilities incurred, assumed or reflected on a consolidated balance sheet of the Credit Parties and their Subsidiaries after giving effect to such Acquisition and the maximum amount of all deferred payments, including the maximum amount of all earnouts, but excluding any such amounts paid or funded with the Net Issuance Proceeds of an Excluded Equity Issuance) for all Acquisitions consummated on or after August 26, 2015 shall not exceed the US Dollar Equivalent of $125,000,000 in the aggregate for all such Acquisitions.

(b)    Deletion of US Dollar Equivalent Limitation on Unsecured Earnouts in Indebtedness Negative Covenant.   Subparagraph (n) in Section 5.5 of the Credit Agreement is hereby amended and restated in its entirety to hereafter be and read as follows:

(n)    unsecured earnouts incurred in connection with a Permitted Acquisition.

Section 5.    Addition of Negative Covenant Permitted Exceptions for Letter of Credit Secured indebtedness.

(a)    Addition of Permitted Liens Exception for Indebtedness Secured by Letter of Credit.   A new Subparagraph (cc) is hereby added to Section 5.1 of the Credit Agreement to hereafter be and read as follows:

(cc)    Liens consisting of pledges or assignments of any Letter of Credit and the proceeds thereof as collateral for Indebtedness permitted pursuant to the terms of Section 5.5(u).

(b)    Addition of Permitted Indebtedness Exception for Indebtedness Secured by Letter of Credit.   A new Subparagraph (u) is hereby added to Section 5.5 of the Credit Agreement to hereafter be and read as follows:

(u)    Indebtedness which is fully backed or secured by one or more Letters of Credit and the proceeds thereof (i.e., the outstanding principal amount of such Indebtedness shall never exceed the aggregate amount remaining available to be drawn under such Letter(s) of Credit), but not any other collateral except to the extent that a Lien on such other collateral as security for such Indebtedness is otherwise permitted under the terms of Section 5.1.

Section 6.     Modification of US Letter of Credit Related Provisions.  

(a)    Modification of Existing Definitions. The definitions of “Canadian L/C Issuer”, “US L/C Issuer”, “US L/C Reimbursement Obligation”, “US Letter of Credit” and 

5

 AUS:0050100/03071:598895v13

“US Letter of Credit Obligations” contained in Section 11.1 of the Credit Agreement are hereby amended and restated in their entirety to hereafter be and read as follow:

“Canadian L/C Issuer” means any Canadian Lender or an Affiliate thereof or a bank or other legally authorized Person, in each case, reasonably acceptable to Canadian Agent, in such Person’s capacity as an issuer of Canadian Letters of Credit hereunder; provided, however, that no Canadian Lender (other than Chase Canada) or its respective Affiliates shall be obligated to issue any Canadian Letter of Credit hereunder, and any issuance by such Canadian Lender (other than Chase Canada) or its respective Affiliates of any Canadian Letter of Credit, if requested by the Canadian Borrower hereunder, shall be at such Canadian Lender’s discretion.
“US L/C Issuer” means any US Revolving Lender or an Affiliate thereof or a bank or other legally authorized Person, in each case, reasonably acceptable to US Agent, in such Person’s capacity as an issuer of Letters of Credit hereunder; provided, however, that no US Revolving Lender (other than Chase) or its respective Affiliates shall be obligated to issue any US Letter of Credit hereunder, and any issuance by such US Revolving Lender (other than Chase) or its respective Affiliates of any US Letter of Credit, if requested by the US Borrower hereunder, shall be at such US Revolving Lender’s discretion.
“US L/C Reimbursement Obligation” means, for any US Letter of Credit, the obligation of the US Borrower to the US L/C Issuer thereof or to US Agent, as and when matured, to pay all amounts drawn under such US Letter of Credit in the same currency in which such drawn amounts were actually paid by the US L/C Issuer thereof to or on behalf of the applicable beneficiary thereunder.
“US Letter of Credit” means documentary or standby letters of credit issued for the account of the US Borrower by US L/C Issuers in denominations of Dollars or other applicable Agreed Currencies requested by US Borrower in accordance with the terms hereof, and bankers’ acceptances issued by US Borrower, for which US Agent and Lenders have incurred US Letter of Credit Obligations.
“US Letter of Credit Obligations” means all outstanding obligations incurred by US Agent and US Revolving Lenders at the request of the US Borrower, whether direct or indirect, contingent or otherwise, due or not due, in connection with the issuance of US Letters of Credit by US L/C Issuers or the purchase of a participation as set forth in subsection 1.1(c) with respect to any US Letter of Credit.  The amount of such US Letter of Credit Obligations shall at any time be equal to the sum of (a) the aggregate undrawn US Dollar Equivalent amount of all outstanding US Letters of Credit at such time plus (b) the aggregate US Dollar Equivalent amount of all payments made by any US L/C Issuers pursuant to a US Letter of Credit that have not yet been reimbursed by or on behalf of the US Borrower at such time.
(b)    Addition of Definitions.   New definitions for the terms “Agreed Currencies,” “Euros”, “Foreign Currency” and “Foreign Currency US Letters of Credit” are hereby added in proper alphabetical order to Section 11.1 of the Credit Agreement to hereafter be and read as follows:
 

6

 AUS:0050100/03071:598895v13

“Agreed Currencies” means (a) Dollars, (b) Euros, (c) British Pounds Sterling, (d) Canadian Dollars, (e) Chinese Renminbi, and (f) any other currency that is (i) a lawful currency (other than Dollars) that is readily available and freely transferable and convertible into Dollars in the international interbank market, (ii) agreed to by the applicable US L/C Issuer and the US Agent, and (iii) is readily available for funding from all of the Lenders. “Agreed Currency” means any of the Agreed Currencies. For the purposes of this definition, each of the specific Foreign Currencies referred to above (other than Euros) shall mean and be deemed to refer to the lawful currency of the jurisdiction referred to in connection with such currency, e.g., “Canadian Dollars” means the lawful currency of Canada.  Notwithstanding the foregoing, if, with respect to any currency designated or approved as an Agreed Currency (including without limitation, any Foreign Currency specified above in the definition of Agreed Currencies), (x) currency controls or other exchange regulations are imposed in the country in which such currency is issued with the result that different types of such currency are introduced, (y) such currency is, in the determination of the US Agent, no longer readily available or freely traded in the international interbank market or (z) in the determination of the US Agent, a US Dollar Equivalent amount of such currency is not readily calculable, the US Agent shall promptly notify US Borrower, and such currency shall no longer be an Agreed Currency for purposes hereof until such time as the US Agent agrees to reinstate such currency as an Agreed Currency.

“Euros” means euros referred to in Council Regulation (EC) No. 1103/97 dated June 17, 1997 passed by the Council of the European Union, or, if different, the then-lawful currency of the member states of the European Union that participate in the third stage of Economic and Monetary Union.

“Foreign Currency” means any Agreed Currency other than Dollars.

“Foreign Currency US Letters of Credit” means US Letters of Credit issued  in any Foreign Currency.

(c)    Modification of Related Mandatory Revolving Loan Prepayment Provisions.  Section 1.1(b) of the Credit Agreement is hereby amended and restated in its entirety to hereafter be and read as follows:

      (b)       The Revolving Credits.

(i)    Subject to the terms and conditions of this Agreement and in reliance upon the representations and warranties of the Credit Parties contained herein, each US Revolving Lender severally and not jointly agrees to make Loans denominated in Dollars to the US Borrower (each such Loan, a “US Revolving Loan”, and for purposes of clarification, the term “US Revolving Loan” shall not include any US Swing Loans and US Letter of Credit Obligations) from time to time on any Business Day during the period from the Closing Date through the Final Availability Date, in an aggregate amount not to exceed at any time outstanding the amount set forth opposite such US Revolving Lender’s name in Schedule 1.1(b) under the heading “US Revolving Loan Commitments” (such amount as the same may be reduced or 

7

 AUS:0050100/03071:598895v13

increased from time to time in accordance with this Agreement, being referred to herein as such US Revolving Lender’s “US Revolving Loan Commitment”); provided, however, that, after giving effect to any Borrowing of US Revolving Loans, the aggregate principal amount of all outstanding US Revolving Loans shall not exceed the Maximum US Revolving Loan Balance.  Subject to the other terms and conditions hereof, amounts borrowed under this subsection 1.1(b)(i) may be repaid and reborrowed from time to time.  The “Maximum US Revolving Loan Balance” from time to time will be equal to the Aggregate US Revolving Loan Commitment then in effect, less the sum of (i) the US Dollar Equivalent of the aggregate amount of US Letter of Credit Obligations, (ii) the aggregate principal amount of outstanding US Swing Loans, (iii) the US Dollar Equivalent of the aggregate principal amount of Canadian Revolving Loans and Canadian Swing Loans, and (iv) the US Dollar Equivalent of the aggregate amount of Canadian Letter of Credit Obligations.  If at any time the then outstanding principal balance of US Revolving Loans exceeds the Maximum US Revolving Loan Balance, then the US Borrower shall prepay, or cause to be prepaid, outstanding Revolving Loans in an amount sufficient to eliminate such excess, within five (5) Business Days after the occurrence thereof; provided, no such prepayment shall be required if such excess (i) does not exceed three percent (3%) of the Maximum US Revolving Loan Balance, (ii) is solely attributable to a change in the exchange rate between Dollars and any Foreign Currencies, and (iii) in no event causes or results in any US Revolving Loans held by any US Revolving Lender to exceed such Lender’s US Revolving Loan Commitment; provided further, however, that any excess amount permitted by the foregoing proviso shall be reduced to zero ($0) within five (5) Business Days after any Agent notifies the US Borrower in writing that such excess has been outstanding for three (3) or more consecutive Business Days and demands payment of such excess as a result.   

(ii)    Subject to the terms and conditions of this Agreement and in reliance upon the representations and warranties of the Credit Parties contained herein, each Canadian Lender severally and not jointly agrees to make Loans denominated in either Dollars or Canadian Dollars to the Canadian Borrower (each such Loan, a “Canadian Revolving Loan” , and for purposes of clarification, the term “Canadian Revolving Loan” shall not include any Canadian Swing Loans and Canadian Letter of Credit Obligations) from time to time on any Business Day during the period from the Closing Date through the Final Availability Date, in an aggregate amount not to exceed at any time outstanding the US Dollar Equivalent of the amount set forth opposite such Canadian Lender’s name in Schedule 1.1(b) under the heading “Canadian Revolving Loan Commitments” (such amount as the same may be reduced or increased from time to time in accordance with this Agreement, being referred to herein as such Canadian Lender’s “Canadian Revolving Loan Commitment”); provided, however, that, after giving effect to any Borrowing of Canadian Revolving Loans, the aggregate principal amount of all outstanding Canadian Revolving Loans shall not exceed the Maximum Canadian Revolving Loan Balance.  Subject to the other terms and conditions hereof, amounts borrowed under this subsection 1.1(b)(ii) may be repaid and reborrowed from time to time.   The “Maximum Canadian Revolving Loan Balance” from time to time will be equal to the Aggregate Canadian Revolving Loan Commitment then in effect, less the sum of (i) the aggregate amount of the US Dollar Equivalent of all Canadian Letter of 

8

 AUS:0050100/03071:598895v13

Credit Obligations, (ii) the US Dollar Equivalent of the aggregate principal amount of outstanding Canadian Swing Loans, (iii) the aggregate principal amount of US Revolving Loans and US Swing Loans, and (iv) the US Dollar Equivalent of aggregate amount of US Letter of Credit Obligations.  If at any time the then outstanding principal balance of Canadian Revolving Loans exceeds the Maximum Canadian Revolving Loan Balance, then the Canadian Borrower shall prepay outstanding Canadian Revolving Loans in an amount sufficient to eliminate such excess, within five (5) Business Days after the occurrence thereof; provided, no such prepayment shall be required if such excess (i) does not exceed three percent (3%) of the Maximum Canadian Revolving Loan Balance, (ii) is solely attributable to a change in the exchange rate between Dollars and any Foreign Currencies, and (iii) in no event causes or results in any Canadian Revolving Loans held by any Canadian Revolving Lender to exceed such Lender’s Canadian Revolving Loan Commitment; provided further, however, that any excess amount permitted by the foregoing proviso shall be reduced to zero ($0) within five (5) Business Days after the Canadian Agent notifies the Canadian Borrower in writing that such excess has been outstanding for five (5) or more consecutive Business Days and demands payment of such excess as a result.   

(d)    Modification of US Letter of Credit Issuance Provisions.   Section 1.1(c) of the Credit Agreement is hereby amended and restated in its entirety to hereafter be and read as follows:

     (c)      US Letters of Credit.

(i)    Conditions.  On the terms and subject to the conditions contained herein, the US Borrower may request that one or more US L/C Issuers Issue, in accordance with such US L/C Issuers’ usual and customary business practices, and for the account of the US Credit Parties, US Letters of Credit (denominated in Dollars or any other applicable Agreed Currency) from time to time on any Business Day during the period from the Closing Date through the earlier of (x) the Final Availability Date and (y) seven (7) days prior to the Revolving Termination Date; provided, however, that no US L/C Issuer shall Issue any US Letter of Credit during the continuance of any of the following or, if after giving effect to such Issuance:

(A)    (i) Aggregate Availability would be less than zero, or (ii) the US Dollar Equivalent of all Letter of Credit Obligations for all Letters of Credit would exceed the US Dollar Equivalent of $25,000,000 (the “L/C Sublimit”); provided, however, that if as of the most recent Computation Date (as defined in clause (viii) below), the aggregate US Dollar Equivalent of all Letter of Credit Obligations for all Letters of Credit exceeds the L/C Sublimit due to exchange rate fluctuations for any Foreign Currency in which outstanding Foreign Currency US Letters of Credit have been issued, then renewals and extensions, but not increases, of previously issued and outstanding US Letters of Credit shall continue to be permitted to be issued hereunder by the applicable US L/C Issuer, notwithstanding the L/C Sublimit continuing to be exceeded, so long as Aggregate Availability would not be 

9

 AUS:0050100/03071:598895v13

less than zero after giving effect to the issuance of such renewal or extension of such previously issued and outstanding US Letters of Credit;  

(B)    the expiration date of such US Letter of Credit (i) is not a Business Day, (ii) is more than one year after the date of issuance thereof (except to the extent expressly permitted in clause (y) below) or (iii) is later than seven (7) days prior to the Revolving Termination Date; provided, however, that (x) any US Letter of Credit with a term not exceeding one year may provide for its renewal for additional periods not exceeding one year as long as (1) each of the US Borrower and such US L/C Issuer have the option to prevent such renewal before the expiration of such term or any such period and (2) neither such US L/C Issuer nor the US Borrower shall permit any such renewal to extend such expiration date beyond the date set forth in clause (iii) above, and (y) US Letters of Credit having an expiration more than one year after the date of issuance thereof, but not longer than three years after the date of issuance thereof, shall be permitted as long as (1) the aggregate US Dollar Equivalent of all Letter of Credit Obligations for all such US Letters of Credit does not exceed the $5,000,000 outstanding at any time, and (2) no such US Letter of Credit shall have an expiration date beyond the date set forth in clause (iii) above; or

(C)    (i) any fee due in connection with, and on or prior to, such Issuance has not been paid, (ii) such US Letter of Credit is requested to be issued in a form that is not acceptable to such US L/C Issuer or (iii) such US L/C Issuer shall not have received, each in form and substance reasonably acceptable to it and duly executed by the US Borrower, the documents that such US L/C Issuer generally uses in the Ordinary Course of Business for the Issuance of letters of credit of the type of such US Letter of Credit (collectively, the “US L/C Reimbursement Agreement”).

Furthermore, any US L/C Issuer, may elect only to issue US Letters of Credit in its own name and may only issue US Letters of Credit to the extent permitted by Requirements of Law, and such US Letters of Credit may not be accepted by certain beneficiaries such as insurance companies.  For each Issuance, the applicable US L/C Issuer may, but shall not be required to, determine that, or take notice whether, the conditions precedent set forth in Section 2.2 have been satisfied or waived in connection with the Issuance of any US Letter of Credit; provided, however, that no US Letters of Credit shall be Issued during the period starting on the first Business Day after the receipt by such US L/C Issuer of notice from US Agent or the Required Lenders that any condition precedent contained in Section 2.2 is not satisfied and ending on the date all such conditions are satisfied or duly waived.

Notwithstanding anything else to the contrary herein, if any US Revolving Lender is a Defaulting Lender, no US L/C Issuer shall be obligated to Issue any US Letter of Credit unless (w) the Defaulting Lender has been replaced in accordance with Section 9.9 or 9.22, (x) the Letter of Credit Obligations of such Defaulting Lender have been cash collateralized, (y) the US Revolving Loan Commitment of each of the other US Revolving Lenders have been increased by an amount sufficient to 

10

 AUS:0050100/03071:598895v13

satisfy US Agent that all future US Letter of Credit Obligations will be covered by all US Revolving Lenders that are not Defaulting Lenders, or (z) the Letter of Credit Obligations of such Defaulting Lender have been reallocated to other Lenders in a manner consistent with subsection 1.12(c).

(ii)    Notice of Issuance.  The US Borrower shall give the relevant US L/C Issuer and US Agent a notice of any requested Issuance of any US Letter of Credit (which shall include the Agreed Currency denomination of the requested US Letter of Credit) which shall be effective only if received by such US L/C Issuer and US Agent not later than 9:00 a.m. (Central time) on the third Business Day prior to the date of such requested Issuance.  Such notice shall be made in a writing or Electronic Transmission substantially in the form of Exhibit 1.1(c) duly completed or in a writing in any other form reasonably acceptable to the L/C Issuer (an “L/C Request”) or by telephone if confirmed promptly in writing or Electronic Transmission.

(iii)    Reporting Obligations of US L/C Issuers.  Each US L/C Issuer agrees to provide US Agent, in form and substance satisfactory to US Agent, each of the following on the following dates: (A) (i) on or prior to any Issuance of any US Letter of Credit by such US L/C Issuer, (ii) immediately after any drawing under any such US Letter of Credit or (iii) immediately after any payment (or failure to pay when due) by the US Borrower of any related US L/C Reimbursement Obligation, notice thereof, which shall contain a reasonably detailed description of such Issuance, drawing or payment (which shall include the Agreed Currency denomination of such Issuance, drawing or payment) and US Agent shall provide copies of such notices to each US Revolving Lender reasonably promptly after receipt thereof; (B) upon the request of US Agent (or any US Revolving Lender through US Agent), copies of any US Letter of Credit Issued by such US L/C Issuer and any related US L/C Reimbursement Agreement and such other documents and information as may reasonably be requested by US Agent; and (C) on the first Business Day of each calendar week, a schedule of the US Letters of Credit Issued by such US L/C Issuer, in form and substance reasonably satisfactory to US Agent, setting forth the US Letter of Credit Obligations for such US Letters of Credit outstanding (including the Agreed Currency denomination of each such outstanding US Letter of Credit) on the last Business Day of the previous calendar week.

(iv)    Acquisition of Participations.  Upon any Issuance of a US Letter of Credit in accordance with the terms of this Agreement resulting in any increase in the US Letter of Credit Obligations, each US Revolving Lender shall be deemed to have acquired, without recourse or warranty, an undivided interest and participation in such US Letter of Credit and the related US Letter of Credit Obligations in an amount equal to its Commitment Percentage of such US Letter of Credit Obligations.

(v)    Reimbursement Obligations of the US Borrower.  The US Borrower agrees to pay to the US L/C Issuer of any US Letter of Credit each US L/C Reimbursement Obligation (said payment to be made in Dollars in an amount equal to the US Dollar Equivalent, determined as of the date of payment by the US L/C Issuer under the applicable US Letter of Credit, of the amounts drawn under such US Letter of Credit and actually paid by the US L/C Issuer thereof to or on behalf 

11

 AUS:0050100/03071:598895v13

of the applicable beneficiary thereunder) owing with respect to such US Letter of Credit no later than the first Business Day after the US Borrower receives notice from such US L/C Issuer that payment has been made under such US Letter of Credit or that such US L/C Reimbursement Obligation is otherwise due (the “US L/C Reimbursement Date”) with interest thereon (payable in Dollars) computed as set forth in clause (A) below.  In the event that any US L/C Reimbursement Obligation is not repaid by the US Borrower as provided in this clause (v) (or any such payment by the US Borrower is rescinded or set aside for any reason), such US L/C Issuer shall promptly notify US Agent of such failure (and, upon receipt of such notice, US Agent shall notify each US Revolving Lender) and, irrespective of whether such notice is given, such US L/C Reimbursement Obligation shall be payable on demand by the US Borrower with interest thereon computed (A) from the date on which such US L/C Reimbursement Obligation arose to the US L/C Reimbursement Date, at the interest rate applicable during such period to US Revolving Loans that are Base Rate Loans and (B) thereafter until payment in full, at the interest rate specified in  subsection 1.3(c) to past due US Revolving Loans that are Base Rate Loans (regardless of whether or not an election is made under such subsection).
(vi)    Reimbursement Obligations of the US Revolving Credit Lenders.

(1)    Upon receipt of the notice described in clause (v) above from US Agent, each US Revolving Lender shall pay to US Agent for the account of such US L/C Issuer its Commitment Percentage of such US Letter of Credit Obligations (as such amount may be increased pursuant to subsection 1.12(c)(i)), said payment to be made in Dollars in an amount equal to the US Dollar Equivalent (determined as of the date of payment by the US L/C Issuer under the applicable US Letter of Credit) of the amounts drawn under such US Letter of Credit and actually paid by the US L/C Issuer thereof to or on behalf of the applicable beneficiary thereunder.
(2)    By making any payment described in clause (1) above (other than during the continuation of an Event of Default under subsection 7.1(f) or 7.1(g)), such US Revolving Lender shall be deemed to have made a US Revolving Loan to the US Borrower in an amount equal to the US Dollar Equivalent of such payment by such US Revolving Lender determined as of the date of such payment, which, upon receipt thereof by such US L/C Issuer, the US Borrower shall be deemed to have used in whole to repay such US L/C Reimbursement Obligation.  Any such payment that is not deemed a US Revolving Loan shall be deemed a funding by such US Revolving Lender of its participation in the applicable US Letter of Credit and the US Letter of Credit Obligation in respect of the related US L/C Reimbursement Obligations.  Such participation shall not otherwise be required to be funded.  Following receipt by any US L/C Issuer of any payment from any US Revolving Lender pursuant to this clause (vi) with respect to any portion of any US L/C Reimbursement Obligation, such US L/C Issuer shall promptly pay over to such US Revolving Lender all duplicate payments received from Persons other than Lenders making payment on behalf of a Credit Party by such US L/C Issuer with respect to such portion of such US L/C Reimbursement Obligation.

12

 AUS:0050100/03071:598895v13

(vii)    Obligations Absolute.  The obligations of the US Borrower and the US Revolving Lenders pursuant to clauses (iv), (v) and (vi) above shall be absolute, unconditional and irrevocable and performed strictly in accordance with the terms of this Agreement irrespective of (A) (i) the invalidity or unenforceability of any term or provision in any US Letter of Credit, any document transferring or purporting to transfer a US Letter of Credit, any Loan Document (including the sufficiency of any such instrument), or any modification to any provision of any of the foregoing, (ii) any document presented under a US Letter of Credit being forged, fraudulent, invalid, insufficient or inaccurate in any respect or failing to comply with the terms of such US Letter of Credit or (iii) any loss or delay, including in the transmission of any document, (B) the existence of any setoff, claim, abatement, recoupment, defense or other right that any Person (including any Credit Party) may have against the beneficiary of any US Letter of Credit or any other Person, whether in connection with any Loan Document or any other Contractual Obligation or transaction, or the existence of any other withholding, abatement or reduction, (C) in the case of the obligations of any US Revolving Lender, (i) the failure of any condition precedent set forth in Section 2.2 to be satisfied (each of which conditions precedent the US Revolving Lenders hereby irrevocably waive) or (ii) any adverse change in the condition (financial or otherwise) of any Credit Party and (D) any other act or omission to act or delay of any kind of either Agent, any Lender or any other Person or any other event or circumstance whatsoever, whether or not similar to any of the foregoing, that might, but for the provisions of this clause (vii), constitute a legal or equitable discharge of any obligation of the US Borrower or any US Revolving Lender hereunder.  No provision hereof shall be deemed to waive or limit the US Borrower’s right to assert claims against, or seek repayment of any payment of any US L/C Reimbursement Obligations from, the US L/C Issuer under the terms of the applicable US L/C Reimbursement Agreement, any other documentation entered into with respect to the relevant Letters of Credit or applicable law.

(viii)    Periodic Computation of US Dollar Equivalent Amount of Foreign Currency US Letters of Credit.  On and as of the last Business Day of each calendar quarter and on any other Business Day elected by the US Agent in its discretion, the US Agent will determine the aggregate US Dollar Equivalent amount of all US Letter of Credit Obligations for outstanding Foreign Currency US Letters of Credit.  Each day upon or as of which the US Agent determines such US Dollar Equivalent amount is herein described as a “Computation Date”. If at any time the aggregate US Dollar Equivalent of all Letter of Credit Obligations for all Letters of Credit exceeds the L/C Sublimit due to exchange rate fluctuations for any Foreign Currencies in which outstanding Foreign Currency US Letters of Credit have been issued (calculated as of the most recent Computation Date), no further US Letters of Credit, whether denominated in Dollars or a Foreign Currency, shall then be issued (other than renewals and extensions, but not increases, of previously issued and outstanding US Letters of Credit, which shall continue to be permitted to be issued hereunder by the applicable US L/C Issuer, notwithstanding the L/C Sublimit continuing to be exceeded) unless and until after giving effect to the issuance of any such additional US Letter of Credit and the determination of the US Dollar Equivalent of all US Letter of Credit Obligations for outstanding Foreign Currency US Letters of Credit 

13

 AUS:0050100/03071:598895v13

(calculated as of the most recent Computation Date), the L/C Sublimit will not be exceeded.  

(e)    Modification of Foreign Currency Payments Provision.   Section 11.4(b) is hereby amended and restated in its entirety to hereafter be and read as follows:

(b)    Interest and principal on all Loans funded in a particular currency will be paid or repaid in that same currency, and interest and principal on all unreimbursed payments made by any US L/C Issuer pursuant to a US Letter of Credit in a particular currency will be paid or repaid in Dollars in an amount equal to the US Dollar Equivalent of the applicable amount determined as of the applicable calculation date in accordance with the other applicable terms of this Agreement; provided that all expense reimbursements hereunder shall be paid in Dollars.  For purposes of preparing financial statements, amounts in any currency other than Dollars will be converted to Dollars based on GAAP, consistently applied, for the purposes of preparing cash flow statements and income statements.  If the Appropriate Agent or any US L/C Issuer receives any payment from or on behalf of any Credit Party in a currency other than the currency in which the relevant Obligation is denominated, the Appropriate Agent or such US L/C Issuer, as applicable, may convert the payment (including the monetary proceeds of realization upon any Collateral and any funds held in a cash collateral account) into the currency in which the relevant Obligation is payable at the exchange rate published in the Wall Street Journal on the Business Day closest in time to the date on which such payment was due (or if such reference is not available, by such other method reasonably determined by Appropriate Agent or such US L/C Issuer, as applicable).  The relevant Obligations shall be satisfied only to the extent of the amount actually received by the Appropriate Agent or the applicable US L/C Issuer, as applicable, upon such conversion.  Unless otherwise specified herein, all determinations of US Dollar Equivalents (calculating financial covenants and determining compliance with covenants expressed in Dollars) shall be determined by reference to the Wall Street Journal published on the Business Day closest in time to the relevant date of determination or for the relevant period of determination or by such other method reasonably determined by the Appropriate Agent in accordance with such Appropriate Agent’s customary practice for commercial loans being administered by it.

Section 7.     Representations and Warranties.  The Credit Parties, jointly and severally, represent and warrant to the Agents, the L/C Issuers and the Lenders that the representations and warranties contained in Article III of the Credit Agreement and in all of the other Loan Documents are true and correct in all material respects on and as of the effective date hereof as though made on and as of such effective date, except to the extent any such representation or warranty is stated to relate solely to an earlier date. The Credit Parties hereby certify that no event has occurred and is continuing which constitutes a Default or an Event of Default under the Credit Agreement.  Additionally, the Credit Parties, jointly and severally, hereby represent and warrant to the Agents, the L/C Issuers and the Lenders that the resolutions of the board of directors of each of the Credit Parties previously delivered to the Agents by the Credit Parties in connection with the execution and delivery of the Credit Agreement (i) remain in full force and effect as of the effective date hereof and have not been modified, amended, superseded or revoked, and (ii) authorize the execution of 

14

 AUS:0050100/03071:598895v13

this Amendment by each of the Credit Parties without the requirement of any further consents, resolutions or authorizations of any of the directors of any of the Credit Parties.   

Section 8.  Conditions Precedent to Effectiveness of this Amendment.  Notwithstanding any provisions to the contrary set forth in this Amendment, the effectiveness of this Amendment is expressly conditioned upon the satisfaction of each of the following:

(a)    the US Agent (or its counsel) shall have received (i) from each party hereto either (A) a counterpart of this Amendment executed on behalf of such party or (B) written evidence satisfactory to the US Agent (which may include facsimile or other electronic transmission of a signed signature page of this Amendment) that such party has signed a counterpart of this Agreement, (ii) from US Borrower either (A) a counterpart of each replacement US Revolving Note of even effective date herewith for each undersigned US Revolving Lender, executed by US Borrower payable to the order of the applicable US Revolving Lender in the amount of such US Revolving Lender’s US Revolving Loan Commitment shown in Schedule 1.1(b) hereto or (B) written evidence satisfactory to the US Agent (which may include facsimile or other electronic transmission of a signed signature page thereof) that US Borrower has signed a counterpart of each such replacement US Revolving Note, (iii) from Canadian Borrower either (A) a counterpart of each replacement Canadian Revolving Note of even effective date herewith for each undersigned Canadian Lender, executed by Canadian Borrower payable to the order of the applicable Canadian Lender in the amount of such Canadian Lender’s Canadian Revolving Loan Commitment shown in Schedule 1.1(b) hereto or (B) written evidence satisfactory to the US Agent (which may include facsimile or other electronic transmission of a signed signature page thereof) that Canadian Borrower has signed a counterpart of each such replacement Canadian Revolving Note, and (iv) from US Borrower either (A) a counterpart of each replacement US Term Note of even effective date herewith for each undersigned US Term Lender, executed by US Borrower payable to the order of the applicable US Term Lender in the outstanding principal amount of the respective US Term Loan of such US Term Lender shown in Exhibit A hereto or (B) written evidence satisfactory to the US Agent (which may include facsimile or other electronic transmission of a signed signature page thereof) that US Borrower has signed a counterpart of each such replacement US Term Note;

(b)    the US Agent shall have received a good standing certificate for each Credit Party from its jurisdiction of organization or the substantive equivalent available in the jurisdiction of organization for each Credit Party from the appropriate governmental officer in such jurisdiction;

(c)    no Default or Event of Default shall have occurred and be continuing as of the effective date of this Amendment; and

(d)    all fees and expenses due and payable by the Borrowers under the terms of the fee letter entered into between the US Agent and the Borrowers in connection with the amendment and modification of the Credit Agreement evidenced by this Amendment shall have been paid in full, and the Agents and the Lenders shall have received all fees required to be paid, and all expenses for which invoices have been presented (including the reasonable fees and expenses of legal counsel), on or before the effective date of this Amendment. 

15

 AUS:0050100/03071:598895v13

Section 9.   Limitations.  The amendments set forth herein are limited precisely as written and shall not be deemed to (a) be a consent to, or waiver or modification of, any other term or condition of the Credit Agreement or any of the other Loan Documents, or (b) except as expressly set forth herein, prejudice any right or rights which the Lenders may now have or may have in the future under or in connection with the Credit Agreement, the Loan Documents or any of the other documents referred to therein.  Except as expressly modified hereby or by express written amendments thereof, the terms and provisions of the Credit Agreement and any other Loan Documents or any other documents or instruments executed in connection with any of the foregoing are and shall remain in full force and effect.  In the event of a conflict between this Amendment and any of the foregoing documents, the terms of this Amendment shall be controlling.    

Section 10.    Ratification.  Except as expressly amended hereby, the Credit Agreement and the other Loan Documents shall remain in full force and effect.  The Credit Agreement, as amended hereby, and all rights and powers created thereby or thereunder and under the other Loan Documents are in all respects ratified and confirmed and remain in full force and effect.  The Credit Parties hereby (a) confirm that each of the respective Collateral Documents previously executed by any US Credit Party apply and shall continue to apply to all Obligations evidenced by or arising pursuant to the Credit Agreement, as amended hereby, or any other Loan Documents, (b) confirm that each of the respective Collateral Documents previously executed by the Canadian Borrower apply and shall continue to apply to all Canadian Obligations evidenced by or arising pursuant to the Credit Agreement, as amended hereby, or any other Loan Documents, and (c) acknowledge that without this ratification and confirmation, the Agents, the Issuing Banks and the Lenders would not agree to the modifications of the Credit Agreement which are evidenced by this Amendment.

Section 11.    Payment of Expenses.  The Credit Parties agree to pay, as set forth in Sections 9.5 and 9.6 of the Credit Agreement, all costs and expenses arising in connection with the preparation, execution and delivery of this Amendment, including, without limitation, the fees and expenses of legal counsel for the Agents.  

Section 12.    Descriptive Headings, etc.  The descriptive headings of the several Sections of this Amendment are inserted for convenience only and shall not be deemed to affect the meaning or construction of any of the provisions hereof.

Section 13.    Entire Agreement.  This Amendment and the documents referred to herein represent the entire understanding of the parties hereto regarding the subject matter hereof and supersede all prior and contemporaneous oral and written agreements of the parties hereto with respect to the subject matter hereof, including, without limitation, any commitment letters regarding the transactions contemplated by this Amendment.

Section 14.   Counterparts.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts and all of such counterparts shall together constitute one and the same instrument.  Complete sets of counterparts shall be lodged with the Borrowers, the Lenders and the Administrative Agents.

16

 AUS:0050100/03071:598895v13

Section 15.    References to Credit Agreement.  As used in the Credit Agreement (including all Exhibits thereto) and all other Loan Documents, on and subsequent to the effective date hereof, the term "Agreement" shall mean the Credit Agreement, as amended by this Amendment.

[Remainder of page left intentionally blank]

17

 AUS:0050100/03071:598895v13

 
            IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective duly authorized officers as of the date first above written.

NOTICE PURSUANT TO TEX. BUS. & COMM. CODE §26.02

THIS AMENDMENT AND ALL OTHER LOAN DOCUMENTS EXECUTED BY ANY OF THE PARTIES BEFORE OR SUBSTANTIALLY CONTEMPORANEOUSLY WITH THE EXECUTION HEREOF TOGETHER CONSTITUTE A WRITTEN CREDIT AGREEMENT AND REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES.  THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

US BORROWER:
THERMON INDUSTRIES, INC. 

	
					
	 
	 
	Name:
	/s/ Rodney Bingham
	 

	 
	 
	Title:
	President and  CEO
	 

CANADIAN BORROWER:
THERMON CANADA INC.
	
					
	 
	 
	Name:
	/s/ Rodney Bingham
	 

	 
	 
	Title:
	Treasurer
	 

OTHER CREDIT PARTIES:
THERMON HOLDING CORP. 
	
					
	 
	 
	Name:
	/s/ Rodney Bingham
	 

	 
	 
	Title:
	President and CEO
	 

    

18

 AUS:0050100/03071:598895v13

THERMON MANUFACTURING COMPANY
	
					
	 
	 
	Name:
	/s/ Rodney Bingham
	 

	 
	 
	Title:
	President and CEO
	 

THERMON HEAT TRACING SERVICES, INC.
	
					
	 
	 
	Name:
	/s/ Rodney Bingham
	 

	 
	 
	Title:
	President
	 

 THERMON HEAT TRACING SERVICES-II, INC.
	
					
	 
	 
	Name:
	/s/ Rodney Bingham
	 

	 
	 
	Title:
	President
	 

THERMON HEAT TRACING SERVICES-I, INC.
	
					
	 
	 
	Name:
	/s/ Rodney Bingham
	 

	 
	 
	Title:
	President
	 

    
    

19

 AUS:0050100/03071:598895v13

AGENTS, ISSUING BANKS     AND LENDERS:
JPMORGAN CHASE BANK, N.A., as US Agent, 
    US Swingline Lender, a US L/C Issuer and
a US Lender
	
					
	 
	 
	Name:
	/s/ Melissa Burnett
	 

	 
	 
	Title:
	Senior Commercial Banker

JPMORGAN CHASE BANK, N.A., TORONTO 
    BRANCH, as Canadian Agent, Canadian 
    Swingline Lender, a Canadian L/C Issuer and     a     Canadian Lender	
					
	 
	 
	Name:
	/s/ Deborah Booth
	 

	 
	 
	Title:
	Vice President
	 

WELLS FARGO BANK, NATIONAL     ASSOCIATION, as a US Term Lender	
					
	 
	 
	Name:
	/s/ Christopher Grover

	 
	 
	Title:
	Vice President
	 

WELLS FARGO BANK, N.A., CANADIAN     BRANCH, as a US Revolving Lender and a     Canadian Lender    	
					
	 
	 
	Name:
	/s/ Mark Beck
	 

	 
	 
	Title:
	Vice President
	 

20

 AUS:0050100/03071:598895v13

BANK OF MONTREAL, 
as a US Lender
	
					
	 
	 
	Name:
	/s/ Thomas Hasenauer

	 
	 
	Title:
	Vice President
	 

BANK OF MONTREAL, 
as a Canadian Lender    
	
					
	 
	 
	Name:
	/s/ R. Wright
	 

	 
	 
	Title:
	Director
	 

BRANCH BANKING AND TRUST COMPANY, 
as a US Lender    
	
					
	 
	 
	Name:
	/s/ Candace C. Moore
	 

	 
	 
	Title:
	Vice President
	 

BRANCH BANKING AND TRUST COMPANY,     as a Canadian Lender    	
					
	 
	 
	Name:
	/s/ Candace C. Moore
	 

	 
	 
	Title:
	Vice President
	 

21

 AUS:0050100/03071:598895v13

EXHIBIT A 
 
Outstanding Principal Amount of US Term Loans (As of August 26, 2015)
Outstanding Principal Amount of US Term Loans
	
		
	JPMorgan Chase Bank, N.A.
	$30,385,321.10

	Wells Fargo Bank, National Association
	$30,385,321.10

	Bank of Montreal
	$21,364,678.90

	Branch Banking and Trust Company
	$21,364,678.90

	 
	 

	Total
	$103,500,000.00

22

 AUS:0050100/03071:598895v13

Schedule 1.1(b) 
 
Revolving Loan Commitments
	
				
	US Revolving Loan Commitments
	 

	 
	 

	JPMorgan Chase Bank, N.A.
	$17,614,678.90

	Wells Fargo Bank, N.A., Canadian 
Branch  
	$17,614,678.90

	Bank of Montreal
	$12,385,321.10

	Branch Banking and Trust Company
	$12,385,321.10

	 
	 

	Total
	$
	60,000,000
	

	 
	 

	 
	 

	Canadian Revolving Loan Commitments
	 

	 
	 

	JPMorgan Chase Bank, N.A., Toronto    Branch
	US$17,614,678.90

	Wells Fargo Bank, N.A., Canadian 
Branch  
	US$17,614,678.90

	Bank of Montreal
	US$12,385,321.10

	Branch Banking and Trust Company
	US$12,385,321.10

	 
	 

	Total
	US$60,000,000

23

 AUS:0050100/03071:598895v13EX-10.1

 Exhibit 10.1 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 
 Master
Manufacturing Services Agreement 
  

Master Manufacturing Services Agreement 

August 3, 2015 

 Master Manufacturing Services Agreement 

 
 Table of Contents 

 

							
	 ARTICLE 1
	  	 	1	  
		
	 STRUCTURE OF AGREEMENT AND INTERPRETATION
	  	 	1	  
			
	 1.1
	 	MASTER AGREEMENT.	  	 	1	  
	 1.2
	 	PRODUCT AGREEMENTS.	  	 	1	  
	 1.3
	 	DEFINITIONS.	  	 	2	  
	 1.4
	 	CURRENCY.	  	 	9	  
	 1.5
	 	SECTIONS AND HEADINGS.	  	 	9	  
	 1.6
	 	SINGULAR TERMS.	  	 	9	  
	 1.7
	 	APPENDIX 1, SCHEDULES AND EXHIBITS.	  	 	9	  
		
	 ARTICLE 2
	  	 	9	  
		
	 PATHEON’S MANUFACTURING SERVICES
	  	 	9	  
			
	 2.1
	 	MANUFACTURING SERVICES.	  	 	9	  
	 2.2
	 	ACTIVE MATERIAL YIELD.	  	 	11	  
		
	 ARTICLE 3
	  	 	13	  
		
	 CLIENT’S OBLIGATIONS
	  	 	13	  
			
	 3.1
	 	PAYMENT.	  	 	13	  
	 3.2
	 	ACTIVE MATERIALS AND QUALIFICATION OF ADDITIONAL SOURCES OF SUPPLY.	  	 	13	  
		
	 ARTICLE 4
	  	 	14	  
		
	 CONVERSION FEES AND COMPONENT COSTS
	  	 	14	  
			
	 4.1
	 	FIRST YEAR PRICING.	  	 	14	  
	 4.2
	 	PRICE ADJUSTMENTS – SUBSEQUENT YEARS’ PRICING.	  	 	14	  
	 4.3
	 	PRICE ADJUSTMENTS – CURRENT YEAR PRICING.	  	 	16	  
	 4.4
	 	ADJUSTMENTS DUE TO TECHNICAL CHANGES.	  	 	16	  
	 4.5
	 	MULTI-COUNTRY PACKAGING REQUIREMENTS.	  	 	17	  
		
	 ARTICLE 5
	  	 	17	  
		
	 ORDERS, SHIPMENT, INVOICING, PAYMENT
	  	 	17	  
			
	 5.1
	 	ORDERS AND FORECASTS.	  	 	17	  
	 5.2
	 	RELIANCE BY PATHEON.	  	 	18	  
	 5.3
	 	MINIMUM ORDERS.	  	 	19	  
	 5.4
	 	SHIPMENTS.	  	 	19	  
	 5.5
	 	LATE DELIVERY.	  	 	19	  
	 5.6
	 	INVOICES AND PAYMENT.	  	 	20	  
		
	 ARTICLE 6
	  	 	21	  
		
	 PRODUCT CLAIMS AND RECALLS
	  	 	21	  

  
 - i - 

 Master Manufacturing Services Agreement 

 
  

							
	 6.1
	 	PRODUCT CLAIMS.	  	 	21	  
	 6.2
	 	PRODUCT RECALLS AND RETURNS.	  	 	21	  
	 6.3
	 	PATHEON’S RESPONSIBILITY FOR NON-CONFORMING AND RECALLED PRODUCTS.	  	 	22	  
	 6.4
	 	DISPOSITION OF DEFECTIVE OR RECALLED PRODUCTS.	  	 	23	  
	 6.5
	 	HEALTHCARE PROVIDER OR PATIENT QUESTIONS AND COMPLAINTS.	  	 	23	  
	 6.6
	 	SOLE REMEDY.	  	 	24	  
		
	 ARTICLE 7
	  	 	24	  
		
	 CO-OPERATION
	  	 	24	  
			
	 7.1
	 	QUARTERLY REVIEW.	  	 	24	  
	 7.2
	 	GOVERNMENTAL AGENCIES.	  	 	24	  
	 7.3
	 	RECORDS AND ACCOUNTING BY PATHEON.	  	 	24	  
	 7.4
	 	INSPECTION.	  	 	24	  
	 7.5
	 	ACCESS.	  	 	25	  
	 7.6
	 	NOTIFICATION OF REGULATORY INSPECTIONS.	  	 	25	  
	 7.7
	 	REPORTS.	  	 	25	  
	 7.8
	 	REGULATORY FILINGS.	  	 	26	  
	 7.9
	 	QUALITY AGREEMENT.	  	 	27	  
		
	 ARTICLE 8
	  	 	27	  
		
	 TERM AND TERMINATION
	  	 	27	  
			
	 8.1
	 	INITIAL TERM.	  	 	27	  
	 8.2
	 	TERMINATION FOR CAUSE.	  	 	27	  
	 8.3
	 	PRODUCT DISCONTINUATION.	  	 	28	  
	 8.4
	 	OBLIGATIONS ON TERMINATION.	  	 	28	  
		
	 ARTICLE 9
	  	 	29	  
		
	 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	29	  
			
	 9.1
	 	AUTHORITY.	  	 	29	  
	 9.2
	 	CLIENT WARRANTIES.	  	 	29	  
	 9.3
	 	PATHEON WARRANTIES.	  	 	30	  
	 9.4
	 	DEBARRED PERSONS.	  	 	31	  
	 9.5
	 	PERMITS.	  	 	31	  
	 9.6
	 	NO WARRANTY.	  	 	31	  
		
	 ARTICLE 10
	  	 	32	  
		
	 REMEDIES AND INDEMNITIES
	  	 	32	  
			
	 10.1
	 	CONSEQUENTIAL DAMAGES.	  	 	32	  
	 10.2
	 	LIMITATION OF LIABILITY.	  	 	32	  
	 10.3
	 	PATHEON INDEMNITY.	  	 	32	  
	 10.4
	 	CLIENT INDEMNITY.	  	 	33	  
		
	 ARTICLE 11
	  	 	33	  

  
 - ii - 

 Master Manufacturing Services Agreement 

 
  

							
	 CONFIDENTIALITY
	  	 	33	  
			
	 11.1
	 	CONFIDENTIAL INFORMATION.	  	 	33	  
	 11.2
	 	USE OF CONFIDENTIAL INFORMATION.	  	 	33	  
	 11.3
	 	EXCLUSIONS.	  	 	34	  
	 11.4
	 	PHOTOGRAPHS AND RECORDINGS.	  	 	34	  
	 11.5
	 	PERMITTED DISCLOSURE.	  	 	34	  
	 11.6
	 	MARKING.	  	 	35	  
	 11.7
	 	RETURN OF CONFIDENTIAL INFORMATION.	  	 	35	  
	 11.8
	 	REMEDIES.	  	 	35	  
		
	 ARTICLE 12
	  	 	35	  
		
	 DISPUTE RESOLUTION
	  	 	35	  
			
	 12.1
	 	COMMERCIAL DISPUTES.	  	 	35	  
	 12.2
	 	TECHNICAL DISPUTE RESOLUTION.	  	 	36	  
		
	 ARTICLE 13
	  	 	36	  
		
	 MISCELLANEOUS
	  	 	36	  
			
	 13.1
	 	INVENTIONS.	  	 	36	  
	 13.2
	 	INTELLECTUAL PROPERTY.	  	 	37	  
	 13.3
	 	INSURANCE.	  	 	37	  
	 13.4
	 	INDEPENDENT CONTRACTORS.	  	 	37	  
	 13.5
	 	NO WAIVER.	  	 	37	  
	 13.6
	 	ASSIGNMENT.	  	 	37	  
	 13.7
	 	FORCE MAJEURE.	  	 	38	  
	 13.8
	 	ADDITIONAL PRODUCT.	  	 	38	  
	 13.9
	 	NOTICES.	  	 	38	  
	 13.10
	 	SEVERABILITY.	  	 	40	  
	 13.11
	 	ENTIRE AGREEMENT.	  	 	40	  
	 13.12
	 	OTHER TERMS.	  	 	40	  
	 13.13
	 	NO THIRD PARTY BENEFIT OR RIGHT.	  	 	40	  
	 13.14
	 	EXECUTION IN COUNTERPARTS.	  	 	40	  
	 13.15
	 	USE OF CLIENT NAME.	  	 	40	  
	 13.16
	 	GOVERNING LAW.	  	 	40	  

  
 - iii - 

 Master Manufacturing Services Agreement 

 
  

 MASTER MANUFACTURING SERVICES AGREEMENT 

THIS MASTER MANUFACTURING SERVICES AGREEMENT (the “Agreement”) is made as of August 3, 2015 (the
“Effective Date”) 
 B E T W E E N: 
  

			
	 	 	PATHEON PHARMACEUTICALS INC.,
		 	a corporation existing under the laws of the State of Delaware
		
		 	(“Patheon”),
		
		 	 - and -

		
		 	ACADIA PHARMACEUTICALS INC.,
		 	a corporation existing under the laws of the State of Delaware
		
		 	(“Client”).

 THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and
for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each Party), and intending to be legally bound the Parties agree as follows: 

ARTICLE 1 
 STRUCTURE
OF AGREEMENT AND INTERPRETATION 
  

	1.1	Master Agreement.  

 This Agreement establishes the general terms and
conditions under which Patheon or any Affiliate of Patheon may perform Manufacturing Services for Client or any Affiliate of Client, at the manufacturing site where the Affiliate of Patheon resides. This “master” form of agreement is
intended to allow the Parties, or any of their Affiliates, to contract for the manufacture of multiple Products through Patheon’s global network of manufacturing sites through the issuance of site specific Product Agreements without having to
re-negotiate the basic terms and conditions contained herein. 
  

	1.2	Product Agreements. 

 This Agreement is structured so that a Product
Agreement may be entered into by the Parties for the manufacture of a particular Product or multiple Products at a Patheon manufacturing site. Each Product Agreement will be governed by the terms and conditions of this Agreement unless the Parties
to the Product Agreement expressly modify the terms and conditions of this Agreement in the Product Agreement. Unless otherwise agreed by the Parties, each Product Agreement will be in the general form and contain the information set forth in
Appendix 1 hereto. 

  
 - 1 - 

 Master Manufacturing Services Agreement 

 
  

	1.3	Definitions. 

 The following terms will have the respective meanings set
out below and grammatical variations of these terms will have corresponding meanings: 
 “Active Materials”, “Active
Pharmaceutical Ingredients” or “API” means the materials listed in a Product Agreement on Schedule D; 
 “Active
Materials Credit Value” means the value of the Active Materials for certain purposes of this Agreement, as set forth in a Product Agreement on Schedule D; 

“Actual Annual Yield” or “AAY” has the meaning specified in Section 2.2(a); 

“Affiliate” means: 
  

	 	(a)	a business entity which owns, directly or indirectly, a controlling interest in a Party to this Agreement, by stock ownership or otherwise; or 

 

	 	(b)	a business entity which is controlled by a Party to this Agreement, either directly or indirectly, by stock ownership or otherwise; or 

 

	 	(c)	a business entity, the controlling interest of which is directly or indirectly common to the controlling interest of a Party to this Agreement; 

For this definition, “control” means the ownership of shares carrying at least a majority of the votes for the election of the
directors of a corporation or other business entity (with corresponding meanings for “controlling interest” and “controlled by”); 

“Annual Minimum” will have the meaning specified in Section 2.1; 

“Annual Product Review Report” means the annual product review report prepared by Patheon as described in Title
21 of the United States Code of Federal Regulations, Section 211.180(e); 
 “Annual Report” means the annual report to
the FDA prepared by Client regarding the Product as described in Title 21 of the United States Code of Federal Regulations, Section 314.81(b)(2); 

“Annual Volume” means the minimum volume of Product to be manufactured in any Year of this Agreement as set forth in a Product
Agreement on Schedule B; 
 “Applicable Laws” means the applicable provisions of any and all national, supranational,
regional, state, provincial, county and local laws, statutes, treaties, ordinances, regulations, rules, administrative codes, guidance, ordinances, by-laws, judgments, decrees, directives, injunctions, permits (including marketing approvals) or
orders of or from any Authority having jurisdiction over or related to the subject item; 
 “Authority” means any
governmental or regulatory authority, department, body or agency or any court, tribunal, bureau, commission or other similar body, whether national, supranational, regional, state, provincial, county or local; 

  
 - 2 - 

 Master Manufacturing Services Agreement 

 
  

 “Batch” means a specific quantity of Product or other material that is
intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of Manufacturing Services; 

“Bill Back Items” means the reasonable documented actual expenses in accordance with Section 2.1(g) for all
third party supplier fees for the purchase or use of columns, standards, tooling, non-standard pallets, PAPR or PPE suits (where applicable), RFID tags and supporting equipment, and other Product-specific items, in each case, as necessary for
Patheon to perform the Manufacturing Services, and which are not included as Components; 
 “Breach Notice” will have the
meaning specified in Section 8.2(a); 
 “Business Day” means a day other than a Saturday, Sunday or a day that is a
statutory holiday in the jurisdiction where the Manufacturing Site is located or in the State of California; 
 “Capital Equipment
Agreement” means a separate agreement that the Parties may enter into that will address responsibility for the purchase of capital equipment and facility modifications that may be required to perform the Manufacturing Services under a
particular Product Agreement; 
 “cGMPs” means, as applicable, current good manufacturing practices as described in: 

 

	 	(a)	Division 2 of Part C of the Food and Drug Regulations (Canada); 

  

	 	(b)	Parts 210 and 211 of Title 21 of the United States’ Code of Federal Regulations; 

  

	 	(c)	EC Directive 2003/94/EC; and 

  

	 	(d)	ICH guidelines; 

 together with the latest Health Canada, FDA, and EMA and any other
jurisdiction agreed to by the Parties guidance documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time, and any foreign equivalents to any such regulations which may apply to the
Manufacturing Site or be applicable to Products sold outside of the United States, Canada or the European Union; 
 “Certificate of
Analysis” means, with respect to a Batch, that document setting for the measured and observable characteristics of Product from the Batch, as required by the Specifications, as dated, executed and provided to Client by Patheon prior to
delivery of the Product; 
 “Certificate of Compliance” means a statement signed by Patheon that certifies that all
Manufacturing Services of a Batch of Product was performed or otherwise implemented, packaged, stored and tested in accordance with cGMP and all other regulatory requirements; 

“Claims” has the meaning specified in Section 10.3; 

“Client Indemnitees” has the meaning specified in Section 10.3; 

“Client Intellectual Property” means Intellectual Property generated or derived by Client or any of its
Affiliates before entering into this Agreement or independent of this Agreement, or by Patheon or any of its Affiliates while performing any Manufacturing Services or otherwise 

  
 - 3 - 

 Master Manufacturing Services Agreement 

 
  

 
generated or derived by Patheon or any of its Affiliates in its business, which Intellectual Property is directly related to, specific to, or dependent upon, Client’s Active Materials or
Product; 
 “Client Property” will have the meaning specified in Section 8.4(e); 

“Client-Supplied Components” means those Components to be supplied by Client or that have been supplied by Client; 

“CMC” has the meaning specified in Section 7.8(c); 

“Components” means, collectively, all packaging components, raw materials, ingredients, and other materials (including labels,
product inserts and other labelling for the Products) required to manufacture the Products in accordance with the Specifications, other than the Active Materials; 

“Confidential Information” has the meaning specified in Section 11.1; 

“DDP” has the meaning as set forth in the 2010 edition of the International Commercial terms published by the
International Chamber of Commerce, as may be amended or modified from time to time (Incoterms 2010); 

“Deficiencies” has the meaning specified in Section 7.8(d); 

“Deficiency Notice” has the meaning specified in Section 6.1(a); 

“Delivery Date” means the date scheduled for shipment of Product under a Firm Order as set forth in
Section 5.1(d); 
 “Delivery Documentation” has the meaning specified in Section 2.1(b); 

“Disclosing Party” has the meaning specified in Section 11.1; 

“Deviation” means a departure from an established quality standard, including, but not limited to, that set
forth in any Product Agreement, any Quality Agreement, cGMP standard operating procedure, manufacturing work order, packaging order, raw material or product specification, analytical control procedure, water monitoring procedure, equipment
maintenance schedule, or any unusual occurrence that could affect the Product. Deviations may be either anticipated or unanticipated departures from established quality standards and may have the potential to affect the safety, identity,
strength, quality or purity of a Product; 
 “EMA” means the European Medicines Agency or any successor agency thereto which
may regulate pharmaceutical products; 
 “EXW” has the meaning as set forth in Incoterms 2010; 

“FDA” means the United States Food and Drug Administration or any successor agency thereto which may regulate pharmaceutical
products; 
 “Firm Order” has the meaning specified in Section 5.1(c); 

“First Firm Order” has the meaning specified in Section 5.1(b); 

  
 - 4 - 

 Master Manufacturing Services Agreement 

 
  

 “For Cause Audit” means an audit of manufacturing records of
Patheon or its subcontractors and supplies by Client following: (a) an unfavorable observation during regulatory inspections that is material to the quality of Product; or (b) a major or repeated quality excursion that may result in a
failed manufacture Batch or Non-Conforming Product; 
 “Force Majeure Event” has the meaning specified in Section 13.7;

 “Health Canada” means the section of the Canadian Government known as Health Canada and includes, among other
departments, the Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate or any successor agency thereto which may regulate pharmaceutical products; 

“Initial Manufacturing Month” has the meaning specified in Section 5.1(b); 

“Initial Manufacturing Period” has the meaning specified in Section 5.1(b); 

“Initial Product Term” has the meaning specified in Section 8.1; 

“Initial Set Exchange Rate” means as of the Effective Date of a Product Agreement, the initial exchange rate set forth in the
Product Agreement to convert one unit of the Patheon Manufacturing Site local currency into one unit of the billing currency, calculated as the daily average interbank exchange rate for conversion of one unit of the Patheon Manufacturing Site local
currency into one unit of the billing currency during the 90 day period immediately preceding the Effective Date as published by OANDA.com “The Currency Site” under the heading “FxHistory: historical currency exchange rates” at
www.OANDA.com/convert/fxhistory; 
 “Initial Term” has the meaning specified in Section 8.1; 

“Intellectual Property” means any and all rights in patents, patent applications, formulae, trademarks, trademark
applications, trade-names, Inventions, copyrights, industrial designs, trade secrets, and know how; 
 “Invention” means any
and all information, results, data, innovation, improvement, development, discovery, computer program, device, trade secret, method, know-how, process, technique or the like, whether or not written or otherwise fixed in any form or medium,
regardless of the media on which it is contained and whether or not patentable or copyrightable; 
 “Inventory” means all
inventories of Components and work-in-process produced or held by Patheon for the manufacture of the Products but, for greater certainty, does not include the Active Materials; 

“Late Delivery” will have the meaning specified in Section 5.5(b); 

“Latent Defect” means a defect in any Batch of Product, the API or Materials that was not, and could not reasonably be
expected to have been, found by exercise of ordinary care, following the approved specifications or in inspection at Delivery; 

“Late Product” means Product ordered under a Firm Order that is not delivered on the Delivery Date; 

“Losses” has the meaning specified in Section 10.3; 

  
 - 5 - 

 Master Manufacturing Services Agreement 

 
  

 “Manufacturing Services” means the manufacturing, quality control, quality
assurance, stability testing, packaging, labelling, storage and related services provided by Patheon to manufacture Product or Products using the Active Materials, Components, and Bill Back Items pursuant to this Agreement; 

“Manufacturing Site” means the facility owned and operated by Patheon where the Manufacturing Services will be performed as
identified in a Product Agreement; 
 “Materials” means all Components and Bill Back Items required to
manufacture the Products in accordance with the Specifications, other than the Active Materials; 
 “Maximum Credit Value”
means the maximum value of Active Materials that may be credited by Patheon under this Agreement, as set forth in a Product Agreement on Schedule D; 

“Minimum Order Quantity” means the minimum number of Batches of a Product to be produced as set forth in a Product Agreement
on Schedule B; 
 “Non-Conforming Products” will have the meaning specified in Section 6.1(a); 

“Out of Specification” or “OOS” means a confirmed result that falls
outside the Specifications. 
 “Party” or “Parties” means, as the context requires
individually or collectively, Patheon and Client; 
 “Patheon Competitor” means a business that derives greater than 50% of
its revenues from performing contract pharmaceutical development or commercial manufacturing services for Third Parties; 
 “Patheon
Indemnitees” has the meaning specified in Section 10.4; 
 “Patheon Intellectual Property” means
Intellectual Property generated or derived by Patheon before performing any Manufacturing Services, or developed by Patheon while performing the Manufacturing Services or otherwise generated or derived by Patheon in its business which Intellectual
Property is not Client Intellectual Property; 
 “Price” means the price measured in US Dollars to be charged by Patheon for
performing the Manufacturing Services, and includes the cost of Components (other than Client-Supplied Components), certain cost items as set forth in a Product Agreement on Schedule B, and annual stability testing costs as set forth in a Product
Agreement on Schedule C; 
 “Product(s)” means the product(s) listed in a Product Agreement on Schedule A; 

“Product Agreement” means the agreement between Patheon and Client issued under this Agreement in the form set forth in
Appendix 1 (including Schedules A to D) under which Patheon will perform Manufacturing Services at a particular Manufacturing Site as updated, amended and revised from time to time by the Parties in accordance with the terms of this Agreement; 

“Product Warranties” will have the meaning specified in Section 9.3(a); 

“Quality Agreement” means the agreement between the Parties entering into a Product Agreement that sets out the quality
assurance standards and responsibilities for the 

  
 - 6 - 

 Master Manufacturing Services Agreement 

 
  

 Manufacturing Services to be performed by Patheon for Client, as such agreement may be
amended from time to time in accordance with its terms; the Parties anticipate that the Quality Agreement will be executed within 30 days after the Effective Date of the Product Agreement; 

“Quantity Converted” as the meaning specified in Section 2.2(a); 

“Quantity Dispensed” has the meaning specified in Section 2.2(a); 

“Quantity Received” has the meaning specified in Section 2.2(a); 

“Quarter” means each successive period of three calendar months commencing on
January 1, April 1, July 1 and October 1; 
 “Recall” means any action (i) by Client or
its Affiliates or licensees to recover title to or possession, or stop distribution, prescription or consumption, of quantities of the Products sold or shipped to Third Parties (including, without limitation, the voluntary withdrawal of Products
from the market); or (ii) by any Regulatory Authorities to detain or destroy any of the Products. Recall will also include any action by Client or its Affiliates or licensees to refrain from selling or shipping quantities of the Products to
Third Parties that would have been subject to a Recall if sold or shipped. 
 “Recipient” has the meaning specified in
Section 11.1; 
 “Regulatory Authority” means the FDA, EMA, and Health Canada and any other foreign regulatory agencies
competent to grant marketing approvals for pharmaceutical products including the Products in the Territory; 

“RFID” means Radio Frequency Identification Devices which (at present or in the future) may be affixed to
Products or Materials to assist in inventory control, tracking, and identification; 
 “Remediation Period” has the meaning
specified in Section 8.2(a); 
 “Set Exchange Rate” means the exchange rate to convert one unit of the Patheon
Manufacturing Site local currency into one unit of the billing currency for each Year, calculated as the average daily interbank exchange rate for conversion of the Patheon Manufacturing Site local currency into one unit of the billing currency
during the full year period (October 1st [preceding year] to September 30th) as published by OANDA.com “The Currency Site” under
the heading “FxHistory: historical currency exchange rates” at www.OANDA.com/convert/fxhistory; 

“Shortfall” has the meaning specified in Section 2.2(b); 

“Significant Quality Event” means any event occurring during the Manufacturing of the Product resulting in a Deviation that
materially impacts the quality, performance, safety or reliability of the Product or intermediates thereof. A confirmed Out of Specification result is a Significant Quality Event; 

“Specifications” means the requirements, for each Material, Component, Active Material or Product, which is given by Client to
Patheon in accordance with the procedures listed in a Product Agreement on Schedule A and which contains documents or requirements relating to each Product, including, without limitation: 

  
 - 7 - 

 Master Manufacturing Services Agreement 

 
  

	 	(a)	specifications for Active Materials and Components; 

  

	 	(b)	manufacturing specifications, directions, and processes; 

  

	 	(c)	storage requirements; 

  

	 	(d)	all environmental, health and safety information for each Product including material safety data sheets; 

  

	 	(e)	the in-process specifications; and 

  

	 	(f)	the finished Product specifications, packaging specifications and shipping requirements for each Product; 

all as updated, amended and revised from time to time by Client in accordance with the terms of this Agreement; 

“Target Yield” has the meaning specified in Section 2.2(a); 

“Target Yield Determination Batches” has the meaning specified in Section 2.2(a); 

“Technical Dispute” has the meaning specified in Section 12.2; 

“Technology Transfer” means the transfer to Client or any Third Party designated by Client by Patheon of all information
relating to the process of manufacturing Product, all documents, manufacturing instructions, specifications, and any other relevant documentation, all relevant manufacturing know-how, licenses and materials (including raw materials specifications)
related to Product that Patheon or its Affiliates, as applicable, controls or has the right to license at any time during the Term and that is necessary to enable Client or its designee to manufacture Product in accordance with the Specifications,
and to comply with applicable regulatory requirements (including obtaining any necessary regulatory approvals, conducting any required studies and developing any other regulatory documentation) and all Applicable Laws in connection with the
transfer; 
 “Territory” means any geographic area described in a Product Agreement where Products manufactured by Patheon
will be distributed by Client; 
 “Third Party” means any party other than Client, Patheon or their respective Affiliates;

 “Third Party Rights” means any Intellectual Property of any party other than Client or Patheon or their respective
Affiliates; 
 “United States” means the United States of America including its territories and possessions; and 

“Year” means in the first year of this Agreement, the period from the Effective Date up to and including December 31 of
the same calendar year, and thereafter will mean a calendar year. 

  
 - 8 - 

 Master Manufacturing Services Agreement 

 
  

	1.4	Currency.  

 Unless otherwise agreed in a Product Agreement, all monetary
amounts expressed in this Agreement are in United States Dollars (USD). 
  

	1.5	Sections and Headings.  

 The division of this Agreement into Articles,
Sections, Subsections, an Appendix, Schedules and Exhibits and the insertion of headings are for convenience of reference only and will not affect the interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement to a
Section, Appendix, Schedule or Exhibit refers to the specified Section, Appendix, Schedule or Exhibit to this Agreement. In this Agreement, the terms “this Agreement”, “hereof”, “herein”,
“hereunder” and similar expressions refer to this Agreement as a whole and not to any particular part, Section, Appendix, Schedule or Exhibit of this Agreement. 

 

	1.6	Singular Terms. 

 Except as otherwise expressly stated or unless the
context otherwise requires, all references to the singular will include the plural and vice versa, and all references to “includes” or “including” will mean “includes without limitation” or “including without
limitation.” 
  

	1.7	Appendix 1, Schedules and Exhibits. 

 Appendix 1 (including Schedules
thereto) and the following Exhibits are attached to, incorporated in, and form part of this Agreement: 
  

					
	Appendix 1	  	-	  	Form of Product Agreement (Including Schedules A to D)
			
	Exhibit A	  	-	  	Technical Dispute Resolution
	Exhibit B	  	-	  	Monthly Active Materials Inventory Report
	Exhibit C	  	-	  	Report of Annual Active Materials Inventory Reconciliation and Calculation of Actual Annual Yield
	Exhibit D	  	-	  	Example of Price Adjustment Due to Currency Fluctuation

 ARTICLE 2 

PATHEON’S MANUFACTURING SERVICES 
  

	2.1	Manufacturing Services. 

 Patheon will perform the Manufacturing Services
for the Territory for the fees specified in a Product Agreement in Schedules B and C. Schedule B to a Product Agreement sets forth a list of cost items that are included or not included in the unit Price for Products; all cost items that are not
included in the Price are subject to additional fees to be paid by the Client as agreed by the Parties. Patheon may amend the fees set out in Schedules B and C to a Product Agreement as set forth and in accordance with Article 4. Patheon will
perform the Manufacturing Services in strict compliance with the established Specifications, cGMP and Applicable Laws. Patheon may not change the Specifications or the Manufacturing Site (including facility modifications) or any other aspect of the
manufacturing process used to perform the Manufacturing Services with respect to the Products except with the prior written consent of Client, this consent not to be unreasonably withheld. Unless otherwise agreed in a Product 

  
 - 9 - 

 Master Manufacturing Services Agreement 

 
  

 
Agreement or in this Agreement, and for so long as Patheon remains in material compliance with its obligations under this Agreement and the applicable Product Agreement, Patheon will manufacture
at least [...***...] % (“Annual Minimum”) of Products manufactured by or on Client’s behalf for sale by Client in the Territory in a particular Year. If Patheon
does not remain in material compliance, the Annual Minimum will no longer apply in addition to any other remedies the Client may have under this Agreement. In performing the Manufacturing Services, Patheon and Client agree that: 

(a) Use of Active Materials and Components. Patheon will use the Active Materials and Components to manufacture Products
in accordance with this Agreement. Patheon will not use the Active Materials, any Client-Supplied Components or any other Components paid for by Client for any other use or purpose. Patheon will use all Active Materials and Components on a first-to-expire, first-to-use basis in manufacturing Products under this Agreement. 

(b) Quality Control and Quality Assurance. Patheon will perform the quality control and quality assurance testing specified in the
Quality Agreement. Batch review and release to Client will be the responsibility of Patheon’s quality assurance group, consistent with the Quality Agreement. Patheon will perform its Batch review and release responsibilities in accordance with
Patheon’s standard operating procedures copies of which have been made available to Client and will not change in a material way related to Product without Client consent (not to be unreasonably withheld), and the Quality Agreement. Each time
Patheon ships Products to Client or Client’s designee, it will give Client a Certificate of Analysis and Certificate of Compliance, and a list of all Deviations (“Delivery Documentation”). Client will have sole responsibility
for the release of Products to the market. The Batch documents, including, but not limited to, Batch production records, lot packaging/labeling records, equipment set up control, operating parameters, investigation/non-conformances, and data
printouts, raw material data, and laboratory notebooks will be the exclusive property of Client. But any intellectual property comprised of the form and style of those Batch documents are the exclusive property of Patheon and Patheon will not be
obligated to disclose to Client confidential or proprietary information of Third Parties contained in any lab notebooks that is unrelated to the Manufacturing Services. Subject to the foregoing, Patheon will provide any information reasonably
required by Client to perform, if required, a Technology Transfer or if requested by a Regulatory Authority in a redacted form at Client’s expense. Except for Patheon Intellectual Property, all information contained in the Batch documents,
including, but not limited to specific Product related information, is Client property. 
 (c) Components. Patheon will purchase
(with the exception of Client-Supplied Components) and test all Components at Patheon’s expense and as required by the Product Agreement in accordance with the Specifications and the Quality Agreement. 

(d) Stability Testing. Patheon will conduct stability testing on the Products as part of the Manufacturing Services provided hereunder.
Patheon will perform this testing in accordance with the protocols set out in the Quality Agreement and the Specifications for the separate fees and during the time periods set out in Schedule C to a Product Agreement, if applicable. Patheon
will not make any changes to these testing protocols without prior written approval from Client. If a confirmed stability test failure occurs, Patheon will notify Client within one Business Day, after which Patheon and Client will jointly determine
the proceedings and methods to be undertaken to investigate the cause of the failure in accordance with the Quality Agreement, including which Party will bear the cost of the investigation. Patheon will not be liable for these costs unless it has
failed to perform the Manufacturing Services in accordance with the Quality Agreement, Specifications, cGMPs or Applicable Laws. Patheon will give Client all stability test data and results (including a final report) at Client’s request within
[...***...] Business Days, upon completion of the testing. 

  
 ***Confidential
Treatment Requested 
 - 10 - 

 Master Manufacturing Services Agreement 

 
  

 (e) Packaging. Patheon will package the Products as set out in the Specifications and
the applicable master packaging records approved by Client. Client will be responsible for the cost of artwork development, as applicable. Patheon will determine and imprint the Batch numbers and expiration dates for each Product shipped. The
expiration dates must be determined in accordance with the Specifications. The Batch numbers and expiration dates will be affixed on the Products and on the shipping carton of each Product as outlined in the Specifications and as required by the
Quality Agreement, cGMPs and Applicable Laws. Client may, in its sole discretion, make changes to labels, product inserts, and other packaging for the Products. Those changes will be submitted by Client to all applicable Regulatory Authorities.
Client will be responsible for the cost of labelling obsolescence when changes occur, as contemplated in Section 4.4. Patheon’s name will not appear on the label or anywhere else on the Products unless: (i) required by any Applicable
Laws; or (ii) Patheon consents in writing to the use of its name. 
 (f) Active Materials and Client-Supplied Components. At
least [...***...] before the scheduled production date, Client will deliver the Active Materials and any Client-Supplied Components to the Manufacturing Site DDP, in sufficient
quantity to enable Patheon to manufacture the desired quantities of Product and to ship Product on the Delivery Date. Upon receipt of the Active Materials, Patheon will test all Active Materials in accordance with the provisions of the Product
Agreement and in accordance with the applicable Quality Agreement. If the Active Materials and/or Client-Supplied Components are not received [...***...] before the scheduled production date, Patheon may delay the shipment of Product by the
same number of days as the delay in receipt of the Active Materials and/or Client-Supplied Components. But if Patheon is unable to manufacture Product to meet this new shipment date due to prior Third Party production commitments, Patheon may delay
the shipment until a later date as agreed to by the Parties, but Patheon will make commercially reasonable efforts to make the shipment as soon as possible. All shipments of Active Material will be accompanied by Certificate(s) of Analysis provided
by Client, confirming the identity and purity of the Active Materials and its compliance with the Active Material Specifications set forth in the Product Agreement. 

(g) Bill Back Items. Bill Back Items purchased by Patheon will be charged to Client at Patheon’s actual and reasonable cost plus a
[...***...]% handling fee for Bill Back Items that cost less than $5,000 and a [...***...]% handling fee for Bill Back Items that cost $5,000 or more, but Client must give prior written approval for the purchase of all Bill Back items.
Patheon will use commercially reasonable efforts to order Bill Back Items in amounts to minimize the handling fee. 
 (h) Handling and
Storage. Patheon will store at no cost to Client inventory to support [...***...] months of production per the forecast of the Active Material and Client-Supplied Components in a controlled and monitored environment and at appropriate
conditions in accordance with Specifications, the Quality Agreement, and Applicable Laws. 
  

	2.2	Active Material Yield.

 (a) Reporting. Patheon will give Client a monthly
inventory report of the Active Materials held by Patheon within five Business Days of the end of the most recent monthly using the inventory report form set out in Exhibit B, which will contain the following information for the month: 

Quantity Received: The total quantity of Active Materials that complies with the Specifications and is received at the Manufacturing
Site during the applicable month (“Quantity Received”). 
 Quantity Dispensed: The total quantity of Active Materials
dispensed at the Manufacturing Site during the applicable month (“Quantity Dispensed”). The Quantity 

  
 ***Confidential
Treatment Requested 
 - 11 - 

 Master Manufacturing Services Agreement 

 
  

 
Dispensed is calculated by adding the Quantity Received to the inventory of Active Materials that complies with the Specifications and is held by Patheon at the beginning of the applicable month,
less the inventory of Active Materials that complies with the Specifications and is held by Patheon at the end of the month. The Quantity Dispensed will only include Active Materials received and dispensed in commercial manufacturing of Products and
will not include any (i) Active Materials that must be retained by Patheon as samples, (ii) Active Materials contained in Product that must be retained as samples, (iii) Active Materials used in testing (if applicable), and
(iv) Active Materials received or dispensed in technical transfer activities or development activities during the applicable period, including without limitation, any regulatory, stability, validation or test Batches manufactured during the
applicable period, in each case of clauses (i) through (iv) in accordance with this Agreement. 
 Quantity Converted: The
total amount of Active Materials contained in the Product manufactured with the Quantity Dispensed (including any additional Product produced in accordance with Section 6.3(a) or 6.3(b)), delivered by Patheon, and not rejected, recalled or
returned in accordance with Section 6.1 or 6.2 because of Patheon’s failure to perform the Manufacturing Services in accordance with Specifications, cGMPs, and Applicable Laws. 

Client acknowledges that, if there is no change in this information from one month to the next month, the report will reflect that. 

Within [...***...] days after the end of each Year, Patheon will prepare an
annual reconciliation of Active Materials on the reconciliation report form set forth in Exhibit C including the calculation of the “Actual Annual Yield” or “AAY” for the Product at each Manufacturing Site during
the Year. AAY is the percentage of the Quantity Dispensed that was converted to Product and is calculated as follows: 
  

			
	Quantity Converted during the Year ×	  	100%
	Quantity Dispensed during the Year	  	

 After Patheon has produced a minimum of [...***...] successful commercial production Batches of Product
and has produced commercial production Batches for at least [...***...] months at the Manufacturing Site (collectively, the “Target Yield Determination Batches”), the Parties will agree on the target yield for the Product at
the Manufacturing Site (each, a “Target Yield”). The Target Yield will be revised annually to reflect the actual manufacturing experience as agreed to by the Parties. 

Additionally, promptly following production of the validation Batches, but prior to production of the [...***...] Target Yield
Determination Batches described above, the Parties will agree to an interim Target Yield that will apply before determination of the Target Yield set out above, based on data from production of the validation Batches. Promptly following production
of the first [...***...] Target Yield Determination Batches described above, the Parties will agree to an updated interim Target Yield that will apply before determination of the Target Yield set out above, based on data from production of the
first [...***...] Target Yield Determination Batches. 
 (b) Shortfall Calculation. If the Actual Annual Yield falls more than
[...***...]% below the respective Target Yield in a Year, then the shortfall for the Year (the “Shortfall”) will be calculated as follows: 

  
 ***Confidential
Treatment Requested 
 - 12 - 

 Master Manufacturing Services Agreement 

 
  

 Shortfall = [(Target Yield – [...***...]%) – AAY] * Active Materials
Credit Value * Quantity Dispensed 
 (c) Credit for Shortfall. If there is a Shortfall for a Product in a Year, then Patheon will
credit Client’s account for the amount of the Shortfall not later than [...***...] days after the end of the Year. 
 Each credit
under this Section 2.2(c) will be summarized on the reconciliation report form set forth in Exhibit C. Upon expiration or termination of a Product Agreement, any remaining credit owing under this Section 2.2 will be paid to Client within
[...***...] days of the expiration or termination of the Product Agreement. The Annual Shortfall, if any, will be disclosed by Patheon on the reconciliation report form. 

(d) Maximum Credit. Patheon’s liability for Active Materials calculated in accordance with this Section 2.2 for any Product
Agreement in a Year will not exceed, in the aggregate, the Maximum Credit Value set forth in Schedule D to the Product Agreement. 
 (e)
No Material Breach. It will not be a material breach of this Agreement by Patheon under Section 8.2(a) if the Actual Annual Yield is less than the Target Yield unless the Actual Annual Yield is more than [...***...]% below the
Target Yield. 
 ARTICLE 3 

CLIENT’S OBLIGATIONS 
  

	3.1	Payment. 

 Client will pay Patheon for performing the Manufacturing
Services in accordance with this Agreement according to the Prices specified in Schedules B and C in a Product Agreement. These Prices may be subject to adjustment under Sections 4.2 and 4.3 of this Agreement. Client will also pay Patheon for
any Bill Back Items as provided in Section 2.1(g). 
  

	3.2	Active Materials and Qualification of Additional Sources of Supply. 

 Client will
at its sole cost and expense, deliver the Active Materials to Patheon (in accordance with Section 2.1(f)). If applicable, Patheon and the Client will reasonably cooperate to permit the import of the Active Materials to the Manufacturing Site.
Client’s obligation will include obtaining the proper release of the Active Materials from the applicable Customs Agency and Regulatory Authority. Client or Client’s designated broker will be the “Importer of Record” for Active
Materials imported to the Manufacturing Site. The Active Materials will be held by Patheon on behalf of Client as set forth in this Agreement. The Active Materials will at all times remain the property of Client. Patheon will ensure that the Active
Materials will not become subject to any encumbrances, liens or other third-party claims while in Patheon’s possession. Any Active Materials received by Patheon will only be used by Patheon to perform the Manufacturing Services. 

If Client asks Patheon to qualify an additional source for the Active Material or any Component, Patheon will evaluate the Active Material or
Component to be supplied by the additional source to determine if it is suitable for use in the Product. The Parties will agree on the scope of work to be performed by Patheon at Client’s cost. For an Active Material, this work at a minimum
will include: 

  
 ***Confidential
Treatment Requested 
 - 13 - 

 Master Manufacturing Services Agreement 

 
  

	 	(a)	laboratory testing to confirm the Active Material meets existing specifications; 

  

	 	(b)	manufacture of an experimental Batch of Product that will be placed on three months accelerated stability; and 

  

	 	(c)	manufacture of three full-scale validation Batches that will be placed on concurrent stability (one Batch may be the registration Batch if manufactured at full scale). 

Section 6.3(c) will apply to all Product manufactured using the newly approved Active Material or Component because of the limited material
characterization that is performed on additional sources of supply. 
 ARTICLE 4 

CONVERSION FEES AND COMPONENT COSTS 
  

	4.1	First Year Pricing. 

 The tiered Price and annual stability Price for the
Products through December 31, 2015 are listed in Schedules B and C in a Product Agreement and are subject to the adjustments set forth in Sections 4.2 and 4.3. 
  

	4.2	Price Adjustments – Subsequent Years’ Pricing. 

 Beginning
January 1, 2016, Patheon may adjust the Price effective January 1st of each Year as follows: 

(a) Manufacturing and Stability Testing Costs. For Products manufactured in the United States or Puerto Rico, Patheon may adjust the
conversion component of Price for inflation, based upon the preliminary number for any increase or decrease in the Producer Price Index pcu325412325412 for Pharmaceutical Preparation Manufacturing published by the United States Department of Labor,
Bureau of Labor Statistics (“PPI”) in August of the preceding Year compared to the final number for the same month of the Year prior to that, unless the Parties otherwise agree in writing. On or before November 30th of each
Year, Patheon will give Client a statement setting forth the calculation for the inflation adjustment to be applied in calculating the Price for the next Year. But Client will have the right to dispute the calculation in good faith and the existing
Prices will continue to apply until the dispute is resolved. If necessary, the Price will be retroactively adjusted for the applicable period after the dispute is resolved. For Products manufactured outside the United States or Puerto Rico, Patheon
may similarly adjust the Price for inflation using an equivalent inflation index to be agreed by the Parties in a Product Agreement. 
 (b)
Component Costs. Patheon may increase or, if the average price of the Component costs decreases, Patheon will decrease the Price for the next Year to pass through the actual additional or reduced Component costs. In November of each Year,
Patheon will give Client reasonably detailed information about the increase or decrease in Component costs which will be applied to the calculation of the Price for the next Year to reasonably demonstrate that the Price increase or decrease is
justified. But Patheon will not be required to give information to Client that is subject to obligations of confidentiality between Patheon and its suppliers. But, at Client’s request, Patheon will allow an independent third party auditor to
review the information supporting the increase or decrease in Component costs and confirm that the information reasonably demonstrates that the Price increase or decrease is justified and reasonable. 

  
 - 14 - 

 Master Manufacturing Services Agreement 

 
  

 (c) Pricing Basis. Client acknowledges that the Price in any Year is quoted based upon
the Minimum Order Quantity and the Annual Volume specified in Schedule B to a Product Agreement. The Price is subject to change if the specified Minimum Order Quantity changes or if the Annual Volume is not ordered in a Year. For greater
clarity, if Patheon and Client agree that the Minimum Order Quantity will be reduced or the Annual Volume in the lowest tier will not be ordered in a Year whether as a result of a decrease in estimated Annual Volume or otherwise and, as a result of
the reduction, Patheon demonstrates to Client’s reasonable satisfaction that its costs to perform the Manufacturing Services or to acquire the Components for the Product will increase or decrease on a per unit basis (including the amount of the
increase), then Patheon may increase or decrease the Price by an amount sufficient to absorb the documented increased or reduced costs. On or before November 1st of each Year, Patheon will
give Client a statement setting forth the information to be applied in calculating those cost increases or decreases for the next Year. But Patheon will not be required to give information to Client that is subject to obligations of confidentiality
between Patheon and its suppliers. But, at Client’s request, Patheon will allow an independent third party auditor to review the information supporting the increase in Component costs and confirm that the information reasonably demonstrates
that the Price increase is justified. 
 (d) Adjustments Due to Currency Fluctuations. If the Parties agree in a Product Agreement to
invoice in a currency other than the local currency for the Manufacturing Site, Patheon will adjust the Price to reflect currency fluctuations in accordance with this Section 4.2(d). If the Set Exchange Rate for a given Year has changed, the
adjustment will be calculated after all other annual Price adjustments under this Section 4.2 have been made. The adjustment will proportionately reflect the increase or decrease, if any, in the Set Exchange Rate compared to the Set Exchange
Rate established for the prior Year or the Initial Set Exchange Rate, as the case may be. An example of the calculation of the price adjustment (for a Canadian Manufacturing Site invoiced in USD) is set forth in Exhibit D. 

(e) Tier Pricing (if applicable). The pricing in Schedule B of a Product Agreement is set forth in Annual Volume tiers based upon the
Client’s volume forecasts under Section 5.1. The Client will be invoiced during the Year for the unit price set forth in the Annual Volume tier based on the [...***...]
month forecast provided in September of the previous Year. Within 30 days of the end of each Year or of the termination of the Agreement, Patheon will send Client a reconciliation of
the actual volume of Product ordered by the Client during the Year with the pricing tiers. If Client has overpaid during the Year, Patheon will issue a credit to the Client for the amount of the overpayment within 45 days of the end of the Year
or will issue payment to the Client for the overpayment within 45 days of the termination of the Agreement. If Client has underpaid during the Year, Patheon will issue an invoice to the Client under Section 5.6 for the amount of the
underpayment within 45 days of the end of the Year or termination of the Agreement. If Client disagrees with the reconciliation, the Parties will work in good faith to resolve the disagreement amicably. If the Parties are unable to resolve the
disagreement within 30 days, the matter will be handled under Section 12.1. 
 For all Price adjustments under this Section 4.2,
Patheon will deliver to Client on or before November 30th of each Year a revised Schedule B to the Product Agreement to be effective for Product delivered on or after the first day of the
next Year, which revised Schedule B must be approved in writing by Client before it becomes binding on the Parties. Client’s approval must not be unreasonably withheld. 

  
 ***Confidential
Treatment Requested 
 - 15 - 

 Master Manufacturing Services Agreement 

 
  

	4.3	Price Adjustments – Current Year Pricing. 

 During any Year, the
Prices set out in Schedule B of a Product Agreement will be adjusted as follows: 
 Extraordinary Increases or Decreases in Component
Costs. If, at any time, market conditions result in Patheon’s cost of Components being materially greater or less than the cost on which the current Price is based, then the Parties will adjust the Price for any affected Product that
reflects the increased or decreased Component costs. Changes materially greater than normal forecasted increases or decreases will have occurred if: (i) the cost of a Component increases or decreases by [...***...]% of the cost for that Component upon which the most recent fee quote was based; or (ii) the aggregate cost for all Components required to manufacture a Product increases or
decreases by [...***...]% of the total Component costs for the Product upon which the most recent fee quote was based. If Component costs have been previously adjusted to reflect an increase or decrease in the cost of one or more Components,
the adjustments set out in (i) and (ii) above will operate based on the last cost adjustment for the Components. 
 For a Price
adjustment under this Section 4.3, Patheon will deliver to Client a revised Schedule B to the Product Agreement and budgetary pricing information, adjusted Component costs or other documents reasonably sufficient to demonstrate that a Price
adjustment is justified, to Client’s reasonable satisfaction. Client will have the right to dispute any Price adjustment in good faith, and for the duration of the dispute, the existing Prices will continue to apply. If necessary, the Price
will be retroactively adjusted for the applicable period after the dispute is resolved. At Client’s request, Patheon will allow an independent Third Party auditor to review the information supporting the increase or decrease in Component costs
and confirm that the information reasonably demonstrates that the Price increase or decrease is justified and reasonable. Patheon will have no obligation to deliver any supporting documents that are subject to obligations of confidentiality between
Patheon and its suppliers. For an undisputed Price adjustment, the revised Price will be effective for any Product delivered on or after the first day of the month following Client’s receipt of the revised Schedule B to the Product Agreement.
If the Price is revised pursuant to this Section 4.3, it will not be revised subsequently pursuant to Section 4.2(b) with respect to the same increased Component costs. 

 

	4.4	Adjustments Due to Technical Changes. 

 Amendments to the Specifications or
the Quality Agreement requested by Client will only be implemented following a technical and cost review that Patheon will perform at Client’s cost, and are subject to Client and Patheon reaching agreement on any Price changes required because
of the amendment. Amendments to the Specifications, the Quality Agreement, or the Manufacturing Site requested by Patheon will only be implemented following the written approval of Client. Upon receiving notice of a request by Client for any such
amendments, Patheon will promptly advise Client in writing of any scheduling adjustments, any cost increases or decreases or other changes that may result from the change, and (a) will use its best efforts to make any change identified in the
Client request that is in response to a regulatory or safety issue pertaining to the Product, and (b) will use commercially reasonable efforts to implement any other change identified in a Client request by the date requested by Client, or as
soon thereafter as it is commercially reasonable. If Client accepts a proposed Price change, the proposed change in the Specifications will be implemented, and the Price change will become effective, only for those orders of Products that are
manufactured under the revised Specifications. In addition, Client agrees to purchase, at Patheon’s actual cost (including all reasonable costs incurred by Patheon for the purchase and handling of the Inventory), all Inventory used under the
“old” Specifications and purchased or maintained by Patheon in order to fill Firm Orders or under Section 5.2, but only to the 

  
 ***Confidential
Treatment Requested 
 - 16 - 

 Master Manufacturing Services Agreement 

 
  

 
extent the Inventory can no longer be used under the revised Specifications. Open purchase orders for Components no longer required under any revised Specifications that were placed by Patheon
with suppliers in order to fill Firm Orders or under Section 5.2 will be cancelled where possible, and if the orders may not be cancelled without penalty, will, at Client’s sole discretion, be assigned to and satisfied by Client or
cancelled by Patheon and Client will reimburse Patheon for any penalty it incurs due to the cancellation. 
  

	4.5	Multi-Country Packaging Requirements.  

 If Client decides to have Patheon
perform Manufacturing Services for the Product for countries outside the Territory, then Client will inform Patheon of the packaging requirements for each such country and Patheon will prepare a quotation for consideration by Client of any
additional costs for Components (other than Client-Supplied Components) and the change over fees for the Product destined for each such country. The agreed additional packaging requirements and related packaging costs and change over fees will be
set out in a written amendment to this Agreement. 
 ARTICLE 5 

ORDERS, SHIPMENT, INVOICING, PAYMENT 
  

	5.1	Orders and Forecasts.  

 (a) Rolling [...***...] Month Forecast. When each Product Agreement is executed, Client will give Patheon a non-binding [...***...] month forecast of the volume of Product that Client expects to order in the
first [...***...] months of commercial manufacture of the Product. This forecast will then be updated by Client on or before the [...***...] day of each month on a rolling forward basis. Client will update the forecast forthwith if it
determines that the volumes estimated in the most recent forecast have changed by more than [...***...]%. The most recent [...***...] month forecast will prevail. 

(b) Firm Orders for Initial Manufacturing Month. At least [...***...] months before the start of commercial manufacture of the
Product, Client will update the rolling forecast for the first [...***...] months of manufacture of the Product (the “Initial Manufacturing Period”). Subject to the provisions of Section 5.1(c), the first month of this
updated forecast (“Initial Manufacturing Month”) will constitute a firm written order in the form of a purchase order or otherwise (“First Firm Order”) by Client to purchase and, when accepted by Patheon, for
Patheon to manufacture the quantity of the Product. If manufacturing has not started, Client may cancel any Batches from the First Firm Order at a cost of $[...***...] per cancelled Batch per month until manufacturing starts, if notice of
cancellation is received by Patheon [...***...] days or more before the scheduled Delivery Date under the First Firm Order. If manufacturing has not started, Client may cancel any Batches from the First Firm Order if notice of cancellation is
received by Patheon more than [...***...] days but fewer than [...***...] days before the scheduled Delivery Date under the First Firm Order, but Client will pay Patheon $[...***...] for each cancelled Batch. The Parties agree that
this payment will be considered liquidated damages for Patheon’s loss of manufacturing capacity due to the Client’s cancellation of manufacturing and will not be considered a penalty. If the First Firm Order is changed or adjusted as
described above, then the initial rolling [...***...] month forecast will also be adjusted as necessary. 
 (c) Firm Orders
Thereafter. Before and during the Initial Manufacturing Period, and on a rolling basis during the term of the Product Agreement, Client will issue an updated [...***...] month forecast on 

  
 ***Confidential
Treatment Requested 
 - 17 - 

 Master Manufacturing Services Agreement 

 
  

 
or before the [...***...] day of each month. This forecast will start on the first day of the next month. The first
[...***...] months of this updated forecast will be considered binding firm orders. But the initial order related to the launch of each Product will not be binding until the Client receives approval from the FDA to market the applicable
Product. Concurrent with the delivery of the applicable forecast, Client will issue a firm written order for the first [...***...] months of the forecast in the form of a purchase order or otherwise (“Firm Order”) by Client to
purchase and, when accepted by Patheon, for Patheon to manufacture and deliver the agreed quantity of the Products as set forth in the Firm Order. The Delivery Date specified in the Firm Order will not be less than ...***... days following the
date that the Firm Order is submitted. Firm Orders submitted to Patheon will specify Client’s purchase order number, quantities by Product type, monthly delivery schedule, and any other elements necessary to ensure the timely manufacture and
shipment of the Products. Upon Patheon’s acceptance of a Firm Order, the quantities of Products ordered in the Firm Order will be firm and binding on the Parties and may only be reduced by written agreement of the Parties. 

(d) [...***...] Year Forecast. On or before the [...***...] day of May of each Year, Client will give Patheon a
written non-binding [...***...]-year forecast, broken down by Quarters [...***...], of the volume of each Product Client then anticipates will be required to be manufactured and delivered to Client during the [...***...]-year
period. 
 (e) Acceptance of Firm Order. Patheon will accept Firm Orders by sending an acknowledgement to Client within
[...***...] Business Days of its receipt of the Firm Order. The acknowledgement will include, subject to confirmation from the Client, the Delivery Date for the Product ordered. The Delivery Date may be amended by written agreement of the
Parties or as set forth in Section 2.1(f) or 5.1(b). If Patheon fails to send an acknowledgement to Client within the applicable [...***...] Business Day period, then the Firm Order will be deemed to have been accepted by Patheon. Patheon
will accept Firm Orders submitted in accordance with this Agreement. If Patheon rejects a Firm Order submitted in accordance with this Agreement, without limiting Client’s other rights and remedies hereunder, Client may obtain the Product from
another supplier, and this Product will not be included for purposes of calculating the Annual Minimum under this Agreement, and the Annual Minimum will automatically be reduced by [...***...]%. If Patheon rejects two or more Firm Orders in a
[...***...]-month period, the Annual Minimum will no longer apply. 
  

	5.2	Reliance by Patheon. 

 (a) Client understands and acknowledges that Patheon
will rely on the Firm Orders and rolling forecasts submitted under Sections 5.1(a) and (b) in ordering the Components (other than Client-Supplied Components) required to meet the Firm Orders. In addition, Client understands that to ensure an
orderly supply of the Components, Patheon may want to purchase the Components in reasonable volumes to meet the production requirements for Products during part or all of the forecasted periods referred to in Section 5.1(a) or to meet the
production requirements of any longer period agreed to in writing by Patheon and Client. Accordingly, Client authorizes Patheon to purchase Components in quantities reasonably needed to satisfy the Manufacturing Services requirements for Products
for the first [...***...] months contemplated in the most recent forecast given by Client under Section 5.1(a). Patheon may make other purchases of Components to meet Manufacturing Services requirements for longer periods if agreed to in
writing by the Parties. The Client will give Patheon written authorization to order Components for any launch quantities of Product requested by Client which will be considered a Firm Order when accepted by Patheon. If Components ordered by Patheon
under Firm Orders or this Section 5.2(a) are not included in finished Products manufactured for Client within [...***...] months after the forecasted month for which the purchases have been made (or for a longer period as the Parties may
agree) or if the Components have expired during the period, then Client will pay to Patheon its costs therefor (including all reasonable costs incurred by Patheon for the purchase and handling of the Components). But if these 

  
 ***Confidential
Treatment Requested 
 - 18 - 

 Master Manufacturing Services Agreement 

 
  

 
Components are used in Products subsequently manufactured for Client or in third party products manufactured by Patheon, Client will receive credit for any costs of those Components previously
paid to Patheon by Client or, at Client’s election, a refund in an amount equal to these costs. On a Quarterly basis, Patheon will provide a report summarizing the Inventory held by Patheon. 

(b) If Client fails to take possession or arrange for the destruction of Components purchased by Patheon in accordance with
Section 5.2(a) within 12 months of purchase or, in the case of finished Product that is not the subject of a Deficiency Notice, within three months of manufacture, Client will pay Patheon $100.00 per pallet, per month thereafter for storing the
Components or finished Product. Storage fees for Components or Product which contain controlled substances or require refrigeration will be charged at $200.00 per pallet per month. Storage fees are subject to a one pallet minimum charge per month.
Patheon may ship finished Product that is not the subject of a Deficiency Notice held by it longer than three months to the Client at Client’s expense on 14 days’ prior written notice to the Client in accordance with the Specifications.

  

	5.3	Minimum Orders. 

 Client may only order Manufacturing Services for amounts
of Products in multiples of the Minimum Order Quantities as set out in Schedule B to a Product Agreement. 
  

	5.4	Shipments. 

 Shipments of Products will be made EXW Patheon’s shipping
point unless otherwise agreed in a Product Agreement. Risk of loss or of damage to Products will remain with Patheon until Patheon loads the Products onto the carrier’s vehicle for shipment at the shipping point at which time risk of loss or
damage will transfer to Client. Patheon will, in accordance with Client’s instructions and as agent for Client, at Client’s risk, (i) arrange for shipping to be paid by Client and (ii) at Client’s expense, obtain any export
license or other official authorization necessary to export the Products. Client will arrange for insurance and will select the freight carrier used by Patheon to ship Products and may monitor Patheon’s shipping and freight practices as they
pertain to this Agreement. Products will be transported in accordance with the Specifications. 
  

	5.5	Late Delivery. 

 (a) Patheon will deliver Products ordered under a Firm
Order on the applicable Delivery Date. The Parties agree that they will work together closely to expedite deliveries of Product, including, without limitation, any samples of Products and Products for initial launch, and manage the scheduling of the
initial Product launch. 
 (b) If, after the Initial Manufacturing Period, Patheon is unable to deliver [...***...]% of the quantity of a particular Product ordered under a Firm Order within [...***...] days of the Delivery Date due to an act or omission by Patheon (a “Late Delivery”),
Client will receive a credit from Patheon for the Late Delivery that will be applied against the purchase price under the next Firm Order. The credit will be [...***...]% of the Price of the quantities of Product not delivered by Patheon under
the Firm Order (i.e., Client Credit = [Quantity Ordered in the Firm Order – Actual Delivery Quantities of Product] * Price [...***...]%). Patheon will make commercially reasonable efforts to replace the late Product within
[...***...] days. If, after the Initial Manufacturing Period, Patheon makes two or more Late Deliveries for the same Product in the same calendar Quarter, Client will receive an additional credit of [...***...]% from Patheon for the Late
Deliveries that will be applied against the purchase price under the next Firm Order. The total credit will be [...***...]% of the Price of the quantities of Product not delivered by Patheon under the Firm Order (i.e., Client Credit =
[Quantity Ordered in the Firm Order – Actual Delivery Quantities of Product] Price [...***...]%. Without 

  
 ***Confidential
Treatment Requested 
 - 19 - 

 Master Manufacturing Services Agreement 

 
  

 
limiting Client’s other rights or remedies in this Agreement, if Patheon makes two or more Late Deliveries within a
[...***...]-month period, the Annual Minimum will be reduced to [...***...]%. In such case, for the remainder of the term of this Agreement, the Parties agree that Patheon will manufacture at least [...***...]% of the Products
manufactured by or on Client’s behalf for sale by Client in the Territory in a particular Year until Patheon has no Late Deliveries for a [...***...] month period in which case the Annual Minimum will increase by [...***...]% and by
[...***...]% in each sequential [...***...] month period that there are no Late Deliveries up to a maximum of [...***...]%. Notwithstanding the foregoing, if Patheon makes two or more Late Deliveries within a
[...***...]-month period, the Parties will meet and agree on and implement a delivery improvement action plan within five Business Days. If, after the delivery improvement plan is in place, two additional Late Deliveries occur within a
[...***...]-month period, these Late Deliveries may be considered a material breach of this Agreement by Patheon under Section 8.2(a) and Patheon will not be allowed any further opportunity to remedy the material breach. 

(c) A Late Delivery will not include any delay in shipment of Product caused by events outside of Patheon’s reasonable control, such as a
Force Majeure Event, a delay in delivery of API or Materials, a delay in Product release approval from Client, inaccurate Client forecasts, or receipt of non-conforming API or Client-Supplied Components. 

 

	5.6	Invoices and Payment. 

 Invoices will be sent by fax or email to the fax number or email
address given by Client to Patheon in writing. Invoices will be sent when the Product is manufactured and released by Patheon to the Client. Patheon will also submit to Client, with each shipment of Products, a duplicate copy of the invoice covering
the shipment and the associated Delivery Documentation. Patheon will also give Client an invoice covering any Inventory or Components which are to be purchased by Client under Section 5.2 of this Agreement. All payments made that are associated
with Inventory or Components will be credited against the Price of any Batch of Product that incorporates the Components and/or Inventory. Each invoice will also reflect any credit to Client under Section 5.2. Each invoice will, to the extent
applicable, identify Client’s Manufacturing Services purchase order number, Product numbers, names and quantities, unit price, freight charges, Delivery Documentation and the total amount to be paid by Client. Client will pay all invoices
within [...***...] days of the date thereof. If any portion of an invoice is disputed, the Client will pay Patheon for the undisputed amount and the Parties will use good faith efforts to reconcile the disputed amount as soon as practicable,
but in no case more than [...***...] days. Interest on undisputed past due accounts will accrue at [...***...]% per month which is equal to an annual rate of [...***...]%. The Late Delivery credits set forth in Section 5.5(b)
are only available to Client if all outstanding undisputed invoices have been paid in full or are within [...***...] days outstanding from the invoice date when the Late Delivery arose. In the case of a Deficiency Notice, payments will be due
within [...***...] days following receipt of a replacement Batch or Batches that are not subject to a Deficiency Notice. Batches that are determined to have a Latent Defect due to Patheon will be either credited against future Batches or
refunded at the sole discretion of Client. No payments will be due for Non-Conforming Product and Patheon will use commercially reasonable efforts to replace the Non-Conforming Product within [...***...] days. 

  
 ***Confidential
Treatment Requested 
 - 20 - 

 Master Manufacturing Services Agreement 

 
  

 ARTICLE 6 

PRODUCT CLAIMS AND RECALLS 
  

	6.1	Product Claims. 

 (a) Product Claims. Client has the right to reject
any shipment of Products or any portion thereof that does not conform to the Product Warranties set forth in Section 9.3(a) (“Non-Conforming Products”), without invalidating any portion of the shipment of Products that conforms
to the Product Warranties. Client will inspect the Products manufactured by Patheon upon receipt at the third-party site agreed to by Patheon and Client and will give Patheon written notice (a “Deficiency Notice”) of all claims for
Non-Conforming Products within [...***...] days after Client’s receipt of the Product and the Delivery Documentation thereof (or, in the case of Latent Defect, within [...***...] days after confirmation by Client, its Affiliate or
any licensee, distributor or other Third Party but not after the expiration date of the Product). If Client fails to give Patheon the Deficiency Notice within the applicable [...***...]- or [...***...]-day period, then the delivery will
be deemed to have been accepted by Client on the [...***...] or [...***...] day after delivery or confirmation, as applicable. Except as set out in Section 6.3, Patheon will have no liability for any Deviations for which it has not
received notice within the applicable [...***...]-day period except for a Latent Defect. 

(b) Determination of Deficiency. Upon receipt of a Deficiency Notice, Patheon will have [...***...] days to advise Client by
notice in writing that it disagrees with the contents of the Deficiency Notice. Should Patheon fail to provide such notice to Client within the [...***...] day period, then Patheon will be deemed to agree with the contents of the Deficiency
Notice. If Client and Patheon fail to agree within [...***...] days after Patheon’s notice to Client as to whether any Products identified in the Deficiency Notice are Non-Conforming Products, then the Parties will mutually select an
independent laboratory or expert to evaluate if the Products are Non-Conforming Products. This evaluation will be binding on the Parties. If the independent laboratory or expert determines that any Products are Non-Conforming Products, Client may
reject those Products in the manner contemplated in this Section 6.1 and Patheon will be responsible for the cost of the evaluation. If the independent laboratory determines that the Products conform to the Product Warranties, then Client will
be deemed to have accepted delivery of the Products on the [...***...] day after delivery (or, in the case of any defects not reasonably susceptible to discovery upon receipt of the Product, on the [...***...] day after confirmation
thereof by Client, but not after the expiration date of the Product) and Client will be responsible for the cost of the evaluation. 
 (c)
Shortages. Claims for shortages in the amount of Products shipped by Patheon will be dealt with by reasonable agreement of the Parties. 
  

	6.2	Product Recalls and Returns. 

 (a) Records and Notice. Patheon and
Client will each maintain records necessary to permit a Recall of any Products delivered to Client or customers of Client. Each Party will promptly notify the other by telephone to the contacts designated in the Quality Agreement (to be confirmed in
writing) of any information which might affect the marketability, safety or effectiveness of the Products or which might result in the Recall or seizure of the Products within one Business Day. Upon receiving this notice or upon this discovery, each
Party will stop making any further shipments of any Products in either Party’s possession or control until Client has made a decision as to whether a Recall or some other corrective action is necessary. The decision to initiate a Recall or to
take some other corrective action, if any, will be made and implemented by Client. 

  
 ***Confidential
Treatment Requested 
 - 21 - 

 Master Manufacturing Services Agreement 

 
  

 (b) Recalls. If (i) any Regulatory Authority issues a directive, order or,
following the issuance of a safety warning or alert about a Product, a written request that any Product be Recalled, (ii) a court of competent jurisdiction orders a Recall, or (iii) Client determines that any Product should be Recalled or
that a “Dear Doctor” letter is required relating the restrictions on the use of any Product, Patheon will co-operate as reasonably required by Client, having regard to all Applicable Laws. 

(c) Product Returns. Client will have the responsibility for handling customer returns of the Products. Patheon will give Client any
assistance that Client may reasonably require to handle the returns including, if requested by Client, appropriate investigations. 
  

	6.3	Patheon’s Responsibility for Non-Conforming and Recalled Products. 

 (a)
Non-Conforming Product. If Client rejects Products under Section 6.1, Client will not be required to pay for the Product under Section 3.1. Patheon will promptly, at Client’s election, either: (i) refund the amount paid
for the Non-Conforming Products if Client previously paid for the Products, and the cost incurred by Client for the Bill Back Items and Client-Supplied Components used in the Products; (ii) offset the amount paid for the Non-Conforming
Products, if Client previously paid for the Products, and the cost incurred by Client for the Bill Back Items and Client-Supplied Components used in the Products, against other amounts due to Patheon hereunder; or (iii) at Patheon’s sole
expense (excluding expense to incur replacement Active Materials, but including the replacement of Client-Supplied Components and Bill Back Items), replace the Products with conforming Products without Client being liable for payment therefor under
Section 3.1, contingent upon the receipt from Client of all Active Materials and Client-Supplied Components required for the manufacture of the replacement Products. For greater certainty, Patheon’s responsibility for any loss of Active
Materials in Non-Conforming Product will be captured and calculated in the Active Materials Yield under Section 2.2. 
 (b) Recalled
Product. If a Recall or return of Products results from, or arises out of, a failure by Patheon to perform the Manufacturing Services in accordance with the terms of this Agreement, including the warranties set forth in Sections 9.3 and 9.4 or
other negligence or willful misconduct of Patheon, Patheon will be responsible for the documented costs and out-of-pocket expenses of the Recall or return and will promptly, at the election of Client, either: (i) refund the amount paid for the
Recalled or returned Products and the cost incurred by Client for the Bill Back Items and Client-Supplied Components used in the Products; (ii) offset the amount paid for the Recalled or returned Products and the cost incurred by Client for the
Bill Back Items and Client-Supplied Components used in the Products, against other amounts due to Patheon hereunder; or (iii) replace the Recalled or returned Products with conforming Products, at Patheon’s sole expense (excluding expense
to incur replacement Active Materials, but including the expense to obtain replacement Bill Back Items and Client-Supplied Components), as promptly as practical without Client being liable for payment therefor under Section 3.1, contingent upon
the receipt from Client of all Active Materials and Client-Supplied Components required for the manufacture of the replacement Products. For greater certainty, Patheon’s responsibility for any loss of Active Materials in Recalled Product will
be captured and calculated in the Active Materials Yield under Section 2.2. In all other circumstances, Recalls, returns, or other corrective actions will be made at Client’s cost and expense. For clarification, any refund of the amount
paid by Client for the Recall or return of Products that is paid by Patheon subject to this Section 6.3(b) will not be considered a liability under, and therefore will not be subject to, Section 10.2(a). 

(c) Product Rejection for Finished Product Specification Failure. Internal process specifications will be defined and agreed upon. If a
Batch or portion of a Batch of Product does not meet a finished Product Specification despite Patheon’s assertion that it manufactured the Product in accordance with the agreed upon process specifications, the Batch production record, and
Patheon’s standard operating procedures for manufacturing, the Parties agree that they will mutually select an 

  
 - 22 - 

 Master Manufacturing Services Agreement 

 
  

 
independent laboratory or expert to evaluate if such laboratory or expert can determine why the Products do not meet a finished Product Specification. The evaluation will be binding on the
Parties. If the independent laboratory or expert determines that the Product is Non-Conforming due to an act or omission by Patheon or does not otherwise comply with the Terms of the Agreement, Client may reject those Products in the manner
contemplated by Section 6.1 and Patheon will be responsible for the cost of the evaluation. If the independent laboratory determines that the Patheon complied with the agreed upon process specifications, the Batch production record, and
Patheon’s standard operating procedures and that the Product does not meet a finished Product specification, Client will be responsible for the cost of the evaluation and will pay Patheon the applicable fee per unit for the Non-Conforming
Product. In which case, the API in the Non-Conforming Product will be included in the “Quantity Converted” for purposes of calculating the “Actual Annual Yield” under Section 2.2(a). 

(d) Except as set forth in Sections 6.3(a) and (b) above, Patheon will not be liable to Client nor have any responsibility to Client for
any deficiencies in, or other liabilities associated with, any Product manufactured by it (collectively, “Product Claims”). For greater clarity, Patheon will have no obligation for any Product Claims to the extent the Product Claim
(i) is caused by deficiencies in the Specifications, the safety, efficacy, or marketability of the Products manufactured in accordance with this Agreement and conforming to the Specifications or any distribution thereof, (ii) results from
a defect in a Component that is not reasonably discoverable by Patheon using the methods set forth in the Specifications or as otherwise provided in this Agreement, (iii) results from a defect in the Active Materials or Client-Supplied
Components that is not reasonably discoverable by Patheon using the methods set forth in the Specifications or as otherwise provided in this Agreement, (iv) is caused by actions of Third Parties occurring after the Product is shipped by Patheon
under Section 5.4, (v) is due to packaging design or labelling defects or omissions for which neither Patheon nor any of its Affiliates or its or their employees, agents or subcontractors has any responsibility, (vi) is due to any
unascertainable reason despite Patheon having performed the Manufacturing Services in accordance with the Quality Agreement, Specifications, cGMPs, Applicable Laws, and the other terms of this Agreement, as determined by an independent laboratory or
expert as set forth in Section 6.3(c) above; or (vii) is due to any other breach by Client of its obligations under this Agreement. 
  

	6.4	Disposition of Defective or Recalled Products. 

 Client will not dispose of
any damaged, defective, returned, Non-Conforming or Recalled Products for which it intends to assert a claim against Patheon without Patheon’s prior written authorization to do so, which will not be unreasonably withheld or delayed.
Alternatively, Patheon may instruct Client to return the Products to Patheon. Patheon will bear the cost of disposition (including any applicable storage fees or the cost of destruction) for any damaged, defective, returned or Recalled Products for
which it bears responsibility under Section 6.1 or 6.3. In all other circumstances, Client will bear the cost of disposition, including all applicable fees for Manufacturing Services, for any damaged, defective, returned, or Recalled Products.

  

	6.5	Healthcare Provider or Patient Questions and Complaints. 

 Client will have
the sole responsibility for responding to questions and complaints from its customers. Questions or complaints received by Patheon from Client’s and its Affiliates’ and licensees’ customers, healthcare providers or patients will be
promptly referred to Client. Patheon will co-operate as reasonably required to allow Client to determine the cause of and resolve any questions and complaints. This assistance will include follow-up investigations, including testing and any other
assistance reasonably requested by Client. In addition, Patheon promptly (and in any event within the timelines specified in the Quality Agreement) will give Client all agreed upon information that will enable Client to respond properly to questions
or complaints about the Products as set forth in the Quality Agreement. 

  
 - 23 - 

 Master Manufacturing Services Agreement 

 
  

 
Client will bear all costs incurred under this Section 6.5, except to the extent the complaint resulted from a failure by Patheon to perform the Manufacturing Services in accordance with the
Specifications, cGMPs, Applicable Laws, and the other terms of this Agreement, in which case those costs incurred under this Section 6.5 will be borne by Patheon. 
  

	6.6	Sole Remedy. 

 Except for the indemnity set forth in Section 10.3 and
subject to the limitations set forth in Sections 10.1 and 10.2, the remedies described in this Article 6 will be Client’s sole remedy for any failure by Patheon to supply Products that conform to the Product Warranties. 

ARTICLE 7 

CO-OPERATION 
  

	7.1	Quarterly Review. 

 Each Party will forthwith upon execution of this
Agreement appoint one of its employees to be a relationship manager responsible for liaison between the Parties. The relationship managers will meet not less than Quarterly to review the current status of the business relationship and manage any
issues that have arisen. 
  

	7.2	Governmental Agencies. 

 Subject to Section 7.8, Patheon may
communicate with any governmental agency, including but not limited to governmental agencies responsible for granting regulatory approval for the Products, regarding the Products only if, in the opinion of Patheon’s counsel, the communication
is necessary to comply with the terms of this Agreement or the requirements of any Applicable Law and a representative of Client is present for a verbal communication or has reviewed and approved a written communication. Patheon will notify Client
immediately upon and in any event within 24 hours after receiving any request from a Regulatory Authority for communication related to a Product. 
  

	7.3	Records and Accounting by Patheon. 

 Patheon will keep records of the
manufacture, testing, and shipping of the Products (including evidence on the testing of raw materials, packaging and labeling materials as required by the Quality Agreement), and retain samples of the Products as are necessary to comply with
applicable manufacturing regulatory requirements, as well as to assist with resolving Product complaints and other similar investigations. Copies of the records and samples will be retained for five years or one year following the date of Product
expiry (whichever is longer), or longer if required by Applicable Laws, at which time Client will be contacted concerning the delivery and destruction of the documents and/or samples of Products at least 45 days prior to the destruction of the
documents or samples. Patheon will not store these documents and/or samples beyond the time period set forth above. 
  

	7.4	Inspection of Financial Records. 

 Client or its designee may inspect
Patheon reports and records relating to this Agreement during normal business hours and with reasonable advance notice of at least [...***...] Business Days, but a Patheon
representative must be present during the inspection. In addition, as more fully set forth in Section 4.2, Client will have the right to allow an independent third party auditor to review the information supporting the price adjustments made
under Sections 4.2, 4.3 and 4.4. 

  
 ***Confidential
Treatment Requested 
 - 24 - 

 Master Manufacturing Services Agreement 

 
  

	7.5	Access. 

 Patheon will give Client reasonable access at agreed times to
procedures and documentation relevant to the Product, and to the areas of the Manufacturing Site in which the Products are manufactured, stored, handled, or shipped, to permit Client to verify that the Manufacturing Services are being performed in
accordance with the Specifications, cGMPs, Applicable Laws and the Quality Agreement. But, with the exception of “For-Cause” Audits, Client will be limited each Year to one cGMP-type audit, lasting no more than [...***...] days, and involving no more than [...***...] auditors. Client may request additional cGMP-type audits, additional audit days, or the participation of additional auditors subject to payment to
Patheon of a fee of $5,000 for each additional audit day and $1,000 per audit day for each additional auditor. The right of access set forth in this Section 7.5 will not include a right to access or inspect Patheon’s financial records. In
addition, upon the request of any Regulatory Authority having jurisdiction over the manufacture of Products hereunder, the Regulatory Authority will have access to observe, audit and inspect any Manufacturing Site and Patheon’s procedures used
for the manufacture, release and stability testing, and/or warehousing of Products and to audit those facilities and procedures for compliance with cGMP and/or other regulatory requirements. Patheon specifically agrees to cooperate with any
inspection by a Regulatory Authority, whether prior to or after Regulatory Approval of a Product, and to provide Client a copy of any inspection or audit report resulting from the inspection within three Business Days from receiving the report.
Client may be present at the Facility for consultation during any such inspection. 
  

	7.6	Notification of Regulatory Inspections. 

 Patheon will notify Client within
one Business Day of any inspection, receipt of notice of any inspection and/or any request for samples by any governmental agency specifically involving the Products. Patheon will also notify Client within three Business Days of receipt of any form
483’s or warning letters or any other significant regulatory action or finding which could directly or indirectly impact the regulatory status of the Products or Patheon’s ability to perform the Manufacturing Services. Within three
Business Days of receipt, Patheon will provide Client with a reasonable description of the notifications and inspections and all supporting documentation, including, as applicable, all form 483’s and warning letters or similar warning or
objection, responses and all other correspondence and discussions of the applicable Regulatory Authority, which should be redacted to protect the confidential information of Third Parties. Patheon will discuss with Client and consider in good faith
any comments provided by Client on the proposed response. Additionally, Patheon will obtain Client’s prior approval of any such responses related to Product. Patheon will use commercially reasonable efforts to address and rectify any issues or
problems in its manufacturing facility or procedures and any objections or warnings raised by the Regulatory Authority as soon as practicable and to continue to manufacture and supply to Client, in compliance with all Applicable Laws and the terms
of this Agreement, the Products ordered by Client. After the filing of a response with the FDA or other Regulatory Authority, Patheon will notify Client of any further contacts with the Regulatory Authority relating to the subject matter of the
response. 
  

	7.7	Reports. 

 Patheon will supply on an annual basis all Product data in its
control, including release test results, complaint test results, and all investigations (in manufacturing, testing, and storage), that Client reasonably requires in order to complete any filing under any applicable regulatory regime, including any
Annual Report that Client is required to file with the FDA or any other Regulatory Authority or other information related to the performance of the Manufacturing Services mandated by a Regulatory Authority. Patheon will promptly provide a copy of
the Annual Product Review Report to the Client at no additional cost. Any additional report requested by Client beyond the scope of cGMPs and customary 

  
 ***Confidential
Treatment Requested 
 - 25 - 

 Master Manufacturing Services Agreement 

 
  

 
FDA or other Regulatory Authority requirements will be subject to an additional fee to be agreed upon between Patheon and the Client. 

 

	7.8	Regulatory Filings.  

 (a) Regulatory Authority. Client will have
the sole right and responsibility for filing all documents with all Regulatory Authorities and taking any other actions that may be required for the receipt and/or maintenance of Regulatory Authority approval for the manufacture, import, export,
distribution, marketing, sale, pricing and/or reimbursement of the Products. Patheon will assist Client, to the extent consistent with Patheon’s obligations under this Agreement, to obtain Regulatory Authority approval for the commercial
manufacture of all Products as quickly as reasonably possible. Client will provide copies of relevant sections of regulatory filings to Patheon that are necessary for Patheon to ensure compliance of the manufacturing processes to those submitted to
Regulatory Authorities. 
 (b) Verification of Data. Prior to filing any documents with any Regulatory Authority that incorporate
data generated by Patheon, Client will give Patheon a copy of the documents incorporating this data to give Patheon the opportunity to verify the accuracy and regulatory validity of those documents as they relate to Patheon generated data. Patheon
requires [...***...] days to perform this review but the Parties may agree to a shorter time for the review as needed, including as mandated by a Regulatory Authority. These documents
will be Confidential Information of Client. 
 (c) Verification of CMC. Prior to filing with any Regulatory Authority any
documentation which is or is equivalent to the FDA’s Chemistry and Manufacturing Controls (all such documentation herein referred to as “CMC”) related to any Marketing Authorization, such as a New Drug Application or
Abbreviated New Drug Application, Client will give Patheon a copy of the CMC as well as all supporting documents which have been relied upon to prepare the CMC that directly relate to the Manufacturing Services provided by Patheon. This disclosure
will permit Patheon to verify that the CMC accurately describes the work that Patheon has performed and the manufacturing processes that Patheon will perform under this Agreement. Patheon requires [...***...] days to perform this review but
the Parties may agree to a shorter time for the review as needed. Client will give Patheon copies of all FDA filings at the time of submission to the extent containing CMC information that directly relate to the Manufacturing Services provided by
Patheon and may redact this information to protect the Confidential Information of any Third Party. 
 (d) Deficiencies. If, in
Patheon’s sole discretion, acting reasonably, Patheon determines that any of the information given by Client under clauses (b) and (c) above is inaccurate or deficient in any material respect (the “Deficiencies”),
Patheon will notify Client in writing of the Deficiencies as promptly as practical and in any case within the time frame set forth in clause (b) or (c), as applicable. The Parties will work together to have the Deficiencies resolved prior to
any pre-approval inspection. 
 (e) Client Responsibility. For clarity, the Parties agree that in reviewing the documents referred to
in clause (b) above, Patheon’s role will be limited to verifying the accuracy of the description of the work undertaken or to be undertaken by Patheon. Subject to the foregoing, Patheon will not assume any responsibility for the accuracy
of any application for receipt of an approval by a Regulatory Authority. The Client is solely responsible for the preparation and filing of the application for approval by the Regulatory Authority and any relevant costs will be borne by the Client.

 (f) Inspection by Regulatory Authorities. If Client does not give Patheon the documents requested under clause (b) above
within the time specified and if Patheon reasonably believes that Patheon’s standing with a Regulatory Authority may be jeopardized, Patheon may, in its sole discretion, delay or postpone any inspection by the Regulatory Authority until Patheon
has reviewed the requested 

  
 ***Confidential
Treatment Requested 
 - 26 - 

 Master Manufacturing Services Agreement 

 
  

 
documents that directly relate to the Manufacturing Services provided by Patheon and is satisfied with their contents. 
  

	7.9	Quality Agreement. 

 For clarification, if there is any conflict between
the terms and conditions of this Agreement, including this Article 7, and the terms and conditions of the Quality Agreement, the terms and conditions of the Quality Agreement will control with regard to topics directly related to quality and
compliance only. 
 ARTICLE 8 

TERM AND TERMINATION 
  

	8.1	Initial Term. 

 This Agreement will become effective as of the Effective
Date and will continue until December 31, 2020 (the “Initial Term”), unless terminated earlier by one of the Parties in accordance herewith. This Agreement will automatically renew after the Initial Term for successive
terms of two Years each if there is a Product Agreement in effect, unless either Party gives written notice to the other Party of its intention to terminate this Agreement at least 24 months prior to the end of the then current term, subject to
earlier termination in accordance with the terms of this Agreement. In any event, the legal terms and conditions of this Agreement will continue to govern any Product Agreement in effect as provided in Section 1.2. Each Product Agreement will
have an initial term of five Years from the start of commercial manufacture at the Manufacturing Site for the Product unless the Parties agree to a different number of Years in the applicable Product Agreement (each, an “Initial Product
Term”), subject to earlier termination in accordance with the terms of this Agreement. Product Agreements will automatically renew after the Initial Product Term for successive terms of two Years each unless either Party gives written
notice to the other Party of its intention to terminate the Product Agreement at least 24 months prior to the end of the then current term, subject to earlier termination in accordance with the terms of this Agreement. 

 

	8.2	Termination for Cause. 

 (a) Either Party at its sole option may terminate
this Agreement or any Product Agreement upon written notice where the other Party has failed to remedy a material breach of any of its representations, warranties, or other obligations under this Agreement or any Product Agreement within
60 days following receipt of a written notice (the “Remediation Period”) of the breach that expressly states that it is a notice under this Section 8.2(a) (a “Breach Notice”). The aggrieved Party’s
right to terminate this Agreement or a Product Agreement under this Section 8.2(a) may only be exercised for a period of 60 days following the expiry of the Remediation Period (where the breach has not been remedied) and if the termination
right is not exercised during this period then the aggrieved Party will be deemed to have waived the breach of the representation, warranty, or obligation described in the Breach Notice. 

(b) Either Party at its sole option may immediately terminate this Agreement or any Product Agreement upon written notice, but without prior
advance notice, to the other Party if: (i) the other Party is declared insolvent or bankrupt by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by the other Party;
or (iii) this Agreement or any Product Agreement is assigned by the other Party for the benefit of creditors. 

  
 - 27 - 

 Master Manufacturing Services Agreement 

 
  

 (c) Client may terminate this Agreement as to any Product and the related Product Agreement
upon at least 30 days’ prior written notice, if any Authority takes any action, or raises any objection, that prevents Client from importing, exporting, purchasing, or selling the Product, or Client (or its Affiliate or licensee) determines
that for safety or efficacy reasons Client is not going to continue to develop or commercialize the Product. But if this occurs, Client must still fulfill all of its obligations under Section 8.4 below and under any Capital Equipment Agreement
regarding the Product. 
 (d) Client may terminate this Agreement or a Product Agreement at any time upon written notice to Patheon, without
limiting Client’s other rights or remedies under this Agreement, if any Authority takes any enforcement action regarding the Manufacturing Site that relates to the Product or could reasonably be expected to adversely affect the ability of
Patheon to supply the Product. 
 (e) Patheon may terminate this Agreement or a Product Agreement upon 18 months’ prior written notice
if Client assigns under Section 13.6 any of its rights under this Agreement or a Product Agreement to an assignee that, in the opinion of Patheon acting reasonably is a Patheon Competitor. But this time period will automatically be extended by
an additional three months if, at 18 months after the notice, Client is working in good-faith to secure, and/or obtain required approvals for, another supplier. 
  

	8.3	Product Discontinuation; Other Causes for Termination by Client. 

 (a)
Client will give at least six months’ advance notice if it intends to no longer order Manufacturing Services for a Product due to this Product’s discontinuance in the market. Upon expiration of the applicable six-month notice period, this
Agreement will terminate with respect to the Product or, if the Product is the only Product subject to this Agreement, this Agreement will terminate in its entirety. 

(b) Except for terminations under the other termination provisions of this Agreement (including Sections 8.2, 8.3(a), 9.4 and 13.7), Client
will give at least 36 months’ advance notice if it intends to no longer order Manufacturing Services for a Product for any other reason. In such case, the Annual Minimum will be reduced
by [...***...]% beginning one year from the date of notice and each year thereafter. Upon expiration of the applicable 36 month period, at Client’s option, this Agreement will
terminate with respect to the Product or, if the Product is the only Product subject to this Agreement, the Agreement will terminate in its entirety. Upon receipt of notice, Patheon will provide assistance to Client in a Technology Transfer. Except
for a material breach of this Agreement by Patheon, Client will be responsible for all costs associated with the Technology Transfer. If the Technology Transfer is a result of a material breach of the Agreement by Patheon, each Party will be
responsible for its own costs associated with the Technology Transfer. In all circumstances, Patheon will use at least commercially reasonable efforts to meet the timeline requested by Client. 

 

	8.4	Obligations on Termination. 

 If a Product Agreement is completed, expires,
or is terminated in whole or in part for any reason, then: 
  

	 	(a)	Client will take delivery of and pay for all undelivered Products that are manufactured and/or packaged under a Firm Order and in compliance with the terms of this Agreement, at the price in effect at the time the Firm
Order was placed; 

  

	 	(b)	Client will purchase, at Patheon’s actual cost (including all costs incurred by Patheon for the purchase and handling of the Inventory), the Inventory applicable to the Products which was purchased, produced and
maintained by Patheon in contemplation of filling Firm Orders or in accordance with Section 5.2; 

  
 ***Confidential
Treatment Requested 
 - 28 - 

 Master Manufacturing Services Agreement 

 
  

	 	(c)	Client will reimburse Patheon for the purchase price payable under Patheon’s orders with suppliers of Components, if the orders were made by Patheon in reliance on Firm Orders or in accordance with
Section 5.2; 

  

	 	(d)	Client acknowledges that no Patheon Competitor will be permitted access to the Manufacturing Site; and 

  

	 	(e)	Client will make commercially reasonable efforts, at its own expense, to remove from Patheon site(s), within 30 days, all unused Active Material and Client-Supplied Components, all applicable Inventory and Materials
(whether current or obsolete), supplies, undelivered Product, chattels, equipment or other moveable property owned by Client, related to the Agreement and located at a Patheon site or that is otherwise under Patheon’s care and control
(“Client Property”). If Client fails to remove the Client Property within 30 days following the completion, termination, or expiration of the Product Agreement, Client will pay Patheon $100.00 per pallet, per month, one pallet
minimum (except that Client will pay $200 per pallet, per month, one pallet minimum, for any of the Client Property that contains controlled substances, requires refrigeration or other special storage requirements) thereafter for storing the Client
Property and will assume any third party storage charges invoiced to Patheon regarding the Client Property. Patheon will invoice Client for the storage charges as set forth in Section 5.5 of this Agreement. 

Any termination or expiration of this Agreement or a Product Agreement will not affect any outstanding obligations or payments due prior to the termination or
expiration, nor will it prejudice any other remedies that the Parties may have under this Agreement or a Product Agreement or any related Capital Equipment Agreement. For greater certainty, expiration or termination of this Agreement or of a Product
Agreement for any reason will not affect the obligations and responsibilities of the Parties under Articles 10, 11 and 12 and Sections 5.4, 5.6, 6.3, 6.4, 6.5, 6.6, 7.3, 7.4, 8.4, 13.1, 13.2, 13.3, 13.11, 13.15 and 13.16, all of which survive any
termination. 
 ARTICLE 9 

REPRESENTATIONS, WARRANTIES AND COVENANTS 
  

	9.1	Authority. 

 Each Party covenants, represents, and warrants to the other
Party, as of the Effective Date, that (a) it has the full right and authority to enter into this Agreement and that it is not aware of any impediment that would inhibit its ability to perform its obligations hereunder and has taken all
necessary action on its part to authorize the performance of the obligations; (b) the execution and delivery of this Agreement and the performance of the Party’s obligations hereunder (i) do not conflict with or violate any
requirement of Applicable Laws or regulations and (ii) do not conflict with, or constitute a default or require any consent under, any contractual obligation of the Party; (c) it is duly organized, validly existing and in good standing
under the laws of the state or country in which it is organized; and (d) this Agreement has been duly executed and delivered on behalf of the Party, and constitutes a legal, valid, binding obligation, enforceable against the Party in accordance
with its terms. 
  

	9.2	Client Warranties. 

 Client covenants, represents, and warrants that: 

 

	 	(a)	Non-Infringement. 

  
 - 29 - 

 Master Manufacturing Services Agreement 

 
  

	 	(i)	the Specifications for each of the Products are its or its Affiliate’s property and Client may lawfully disclose the Specifications to Patheon; 

 

	 	(ii)	any Client Intellectual Property provided by Client for use by Patheon in performing the Manufacturing Services according to the Specifications and the other terms of this Agreement (i) is owned or controlled by
Client or its Affiliate, (ii) may be lawfully used by Patheon as directed by Client, and (iii) when used by Patheon according to the Specifications and the other terms of this Agreement does not infringe any Third Party Rights known to
Client; 

  

	 	(iii)	subject to [...***...], the [...***...] or the [...***...]; 

 

	 	(iv)	as of the Effective Date, there are no actions or other legal proceedings to which the Client is a party or of which Client is aware, concerning the infringement of Third Party Rights related to any of the
Specifications, or any of the Active Materials and the Client-Supplied Components, or the sale, use, or other disposition of any Product made in accordance with the Specifications; 

 

	 	(b)	Quality and Compliance.  

  

	 	(i)	the Specifications for all Products conform to all applicable cGMPs and Applicable Laws; 

  

	 	(ii)	once Client has received approval from the FDA to market the Products, the Products, if labelled and manufactured in accordance with the Specifications and in compliance with applicable cGMPs and Applicable Laws
(i) may be lawfully sold and distributed in every jurisdiction in which Client markets the Products and (iii) will be safe for human consumption; 

  

	 	(iii)	on the date of shipment to the Manufacturing Site, the API will conform to the specifications for the API that Client has given to Patheon, subject to Patheon’s obligation to test the API in accordance with the
Quality Agreement before beginning manufacture of the Products using the API, and that the API will be adequately contained, packaged, and labelled and will conform to the affirmations of fact on the container. 

 

	9.3	Patheon Warranties. 

 Patheon covenants, represents, and warrants that:

  

	 	(a)	(1) all Products delivered hereunder will (i) conform to the applicable Specifications; (ii) be free and clear of any and all encumbrances, liens, or other third party claims; (iii) be manufactured,
packaged, labelled and delivered in compliance with the Quality Agreement and applicable cGMP, all regulatory approvals for the Product, and Applicable Laws and in accordance with manufacturing procedures described in the applicable master Batch
records for the Product; (iv) not be adulterated or misbranded within the meaning of the 

  
 ***Confidential
Treatment Requested 
 - 30 - 

 
Master Manufacturing Services Agreement 
  

 

	 	
United States Food, Drug and Cosmetic Act, as amended, and any regulations promulgated thereunder or comparable provisions under the laws and regulations of any other applicable jurisdiction (the
“Act”); and (v) not be articles that, under the provisions of the Act, may not be introduced into interstate commerce; and (2) Patheon’s processes used to perform the Manufacturing Services will not infringe on any
Third Party Rights (collectively, the “Product Warranties”); 

  

	 	(b)	it will perform the Manufacturing Services in accordance with the Quality Agreement, Specifications, cGMPs, and Applicable Laws; 

  

	 	(c)	the Components, Active Materials and the Bill Back Items will at all times be free and clear of any and all encumbrances, liens, or other third party claims; and 

 

	 	(d)	any Patheon Intellectual Property used by Patheon to perform the Manufacturing Services (i) is Patheon’s or its Affiliate’s unencumbered property, (ii) may be lawfully used by Patheon, and
(iii) does not infringe and will not infringe any Third Party Rights. 

  

	9.4	Debarred Persons. 

 Patheon covenants that it will not in the performance
of its obligations under this Agreement use the services of any person debarred or suspended under 21 U.S.C. §335(a) or (b) or comparable provisions under the laws and regulations of any other applicable jurisdiction. Patheon represents
that it does not currently have, and covenants that it will not hire, as an officer or an employee any person who has been convicted of a felony under the laws of the United States for conduct relating to the regulation of any drug product under the
Act. If Patheon or any officer, employee or agent of Patheon: (a) becomes debarred; or (b) receives notice of action or threat of action with respect to its debarment, during the term of this Agreement, Patheon agrees to notify Client
immediately. If Patheon or any of its officers, employees or agents becomes debarred as set forth in clause (a) above or receives notice of action or threat of action as set forth in clause (b) above, Client will have the right to
terminate this Agreement upon written notice to Patheon. 
  

	9.5	Permits. 

 Client will be solely responsible for obtaining or maintaining,
on a timely basis, any permits or other regulatory approvals for the Products or the Specifications, including, without limitation, all marketing and post-marketing approvals. 

Patheon will maintain at all relevant times all governmental permits, licenses, approval, and authorities required to enable it to lawfully
and properly perform the Manufacturing Services. 
  

	9.6	No Warranty. 

 NEITHER PARTY MAKES ANY WARRANTY OR REPRESENTATION OF ANY
KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. WITHOUT LIMITING THE FOREGOING, NEITHER PARTY MAKES ANY WARRANTY OR REPRESENTATION OF FITNESS FOR A PARTICULAR PURPOSE NOR ANY WARRANTY OR
REPRESENTATION OF MERCHANTABILITY FOR THE PRODUCTS. 

  
 - 31 - 

 Master Manufacturing Services Agreement 

 
  

 ARTICLE 10 

REMEDIES AND INDEMNITIES 
  

	10.1	Consequential Damages. 

 Except for liability for breach by either Party of
its obligations of Confidentiality under Article 11, under no circumstances whatsoever will either Party be liable to the other in contract, tort, negligence, breach of statutory duty, or otherwise for (i) any (direct or indirect) loss of
profits, of production, of anticipated savings, of business, or goodwill or (ii) for any other liability, damage, costs, or expense of any kind incurred by the other Party of an indirect or consequential nature, regardless of any notice of the
possibility of these damages. This Section 10.1 will not be deemed to limit either Party’s indemnification obligations under this Article 10. 
  

	10.2	Limitation of Liability. 

 (a) Active Materials. Except as expressly
set forth in Section 2.2 and Section 6, under no circumstances will Patheon be responsible for any loss or damage to the Active Materials. Patheon’s maximum responsibility per Year for loss or damage to the Active Materials will not
exceed the Maximum Credit Value set forth in Schedule D of a Product Agreement. 
 (b) Maximum Liability. Subject to
Section 10.2(c) and excluding Patheon’s indemnity obligations arising under Section 10.3, Patheon’s maximum liability to Client per Year under this Agreement or the Product Agreement for a single Product for any reason
whatsoever, including, without limitation, any liability arising under Article 6 hereof or resulting from any and all breaches of its representations, warranties, or any other obligations under this Agreement or the applicable Product Agreement will
not exceed on a per Product basis [...***...]. 
 (c) Nothing contained in
this Agreement will exclude or limit either Party’s liability for personal injury, death or fraudulent misrepresentation. 
  

	10.3	Patheon Indemnity. 

 (a) Patheon agrees to defend and indemnify Client, its
Affiliates and licensees, and their respective directors, officers, employees, and agents (“Client Indemnitees”) against all losses, damages, costs, judgments, liability, fees and expenses (including reasonable attorneys’ fees)
(collectively, “Losses”) incurred by any Client Indemnitee due to any suit, claim, demand, judgment or action brought by any Third Parties (other than Affiliates) (each, a “Claim”), including, without limitation any
Claim of personal injury or property damage, to the extent that the injury or damage is the result of (a) a failure by Patheon or any of its Affiliates to perform the Manufacturing Services in accordance with the Specifications, cGMPs, and
Applicable Laws, (b) Patheon’s breach of any of its obligations, representations or warranties under this Agreement, or (c) the negligence or willful misconduct of any Patheon Indemnitee except to the extent that the losses, damages,
costs, claims, demands, judgments, and liability are due to the negligence or willful misconduct of any Client Indemnitee. 
 (b) If a Claim
occurs, Client will: (a) promptly notify Patheon of the Claim; (b) use commercially reasonable efforts to mitigate the effects of the Claim; (c) reasonably cooperate with Patheon in the defense of the claim; and (d) permit
Patheon to control the defense and settlement of the claim, all at Patheon’s cost and expense. Notwithstanding the foregoing, Patheon will not compromise or 

  
 ***Confidential
Treatment Requested 
 - 32 - 

 Master Manufacturing Services Agreement 

 
  

 
settle any Claim for which a Client Indemnitee is requesting indemnification for any damages other than monetary damages without Client’s prior written consent, which will not be
unreasonably withheld. 
  

	10.4	Client Indemnity. 

 (a) Client agrees to defend and indemnify Patheon and
its Affiliates and their respective directors, officers, employees, and agents (“Patheon Indemnitees”) against all Losses, incurred by any Patheon Indemnitee due to any Claim of infringement or alleged infringement of any Third
Party Rights in the Products, or any Claim of personal injury or property damage, in each case, to the extent that the Losses are the result of a breach of this Agreement by Client, including, without limitation, any representation or warranty
contained herein, or the negligence or wilful misconduct of any Client Indemnitee, except to the extent that the Losses are due to the negligence or willful misconduct of any Patheon Indemnitee. 

(b) If a Claim occurs, Patheon will: (a) promptly notify Client of the Claim; (b) use commercially reasonable efforts to mitigate
the effects of the Claim; (c) reasonably cooperate with Client in the defense of the Claim; and (d) permit Client to control the defense and settlement of the Claim, all at Client’s cost and expense. Notwithstanding the foregoing,
Client will not compromise or settle any Claim for which a Patheon Indemnitee is requesting indemnification for any damages other than monetary damages without Patheon’s prior written consent, which will not be unreasonably withheld. 

ARTICLE 11 

CONFIDENTIALITY 
  

	11.1	Confidential Information. 

 “Confidential Information”
means any information disclosed by the Disclosing Party to the Recipient (whether disclosed in oral, written, electronic or visual form) that is non-public, confidential or proprietary including, without limitation, information relating to the
Disclosing Party’s patent and trademark applications, process designs, process models, drawings, plans, designs, data, databases and extracts therefrom, formulae, methods, know-how and other intellectual property, its clients or client
confidential information, finances, marketing, products and processes and all price quotations, manufacturing or professional services proposals, information relating to composition, proprietary technology, and all other information relating to
manufacturing capabilities and operations. In addition, all analyses, compilations, studies, reports or other documents prepared by any Party’s Representatives containing the Confidential Information will be considered Confidential Information.
Samples or materials provided hereunder as well as any and all information derived from the approved analysis of the samples or materials will also constitute Confidential Information. For the purposes of this ARTICLE 11, a Party or its
Representative receiving Confidential Information under this Agreement is a “Recipient,” and a Party or its Representative disclosing Confidential Information under this Agreement is the “Disclosing Party.” 

 

	11.2	Use of Confidential Information.  

 The Recipient will use the Confidential
Information solely for the purpose of meeting its obligations under this Agreement. The Recipient will keep the Confidential Information strictly confidential and will not disclose the Confidential Information in any manner whatsoever, in whole or
in part, other than to those of its Representatives who (i) have a need to know the Confidential Information for the purpose of this Agreement; (ii) have been advised of the confidential nature of the Confidential Information and
(iii) have obligations of confidentiality and non-use to the Recipient no less restrictive than those of this Agreement. Additionally, Client will have the right to disclose Confidential Information

  
 - 33 - 

 Master Manufacturing Services Agreement 

 
  

 
to sublicensees and/or other strategic partners or in connection with financings or similar transactions provided that the parties to whom Client discloses this information are bound by
obligations of confidentiality and non-use no less restrictive than those of this Agreement. Recipient will protect the Confidential Information disclosed to it by using all reasonable precautions to prevent the unauthorized disclosure,
dissemination or use of the Confidential Information, which precautions will in no event be less than those exercised by Recipient with respect to its own confidential or proprietary Confidential Information of a similar nature. The obligations of
confidentiality and non-use set forth in this Article 11 will remain in effect for a period of seven years following the termination of this Agreement. 
  

	11.3	Exclusions. 

 The obligations of confidentiality will not apply to the
extent that the information: 
 (a) is or becomes publicly known through no breach of this Agreement or fault of the Recipient or its
Representatives; 
 (b) is in the Recipient’s possession at the time of disclosure by the Disclosing Party other than as a result of
the Recipient’s breach of any legal obligation; 
 (c) is or becomes known to the Recipient on a non-confidential basis through
disclosure by sources, other than the Disclosing Party, having the legal right to disclose the Confidential Information, provided that the other source is not known by the Recipient to be bound by any obligations (contractual, legal, fiduciary, or
otherwise) of confidentiality to the Disclosing Party with respect to the Confidential Information; 
 (d) is independently developed by the
Recipient without use of or reference to the Disclosing Party’s Confidential Information as evidenced by Recipient’s written records; or 

(e) is expressly authorized for release by the written authorization of the Disclosing Party. 

Any combination of information which comprises part of the Confidential Information are not exempt from the obligations of confidentiality
merely because individual parts of that Confidential Information were publicly known, in the Recipient’s possession, or received by the Recipient, unless the combination itself was publicly known, in the Recipient’s possession, or received
by the Recipient. 
  

	11.4	Photographs and Recordings. 

 Neither Party will take any photographs or
videos of the other Party’s facilities, equipment or processes, nor use any other audio or visual recording equipment (such as camera phones) while at the other Party’s facilities, without that Party’s express written consent. 

 

	11.5	Permitted Disclosure. 

 Notwithstanding any other provision of this
Agreement, the Recipient may disclose Confidential Information of the Disclosing Party to the extent required, as advised by counsel, in response to a valid order of a court or other governmental body or as required by law, regulation or stock
exchange rule. But the Recipient will advise the Disclosing Party in advance of the disclosure to the extent practicable and permissible by the order, law, regulation or stock exchange rule and any other applicable law, will reasonably cooperate
with the Disclosing Party, if required, in seeking an appropriate protective order or other remedy, and will otherwise continue to perform its obligations of confidentiality set out 

  
 - 34 - 

 Master Manufacturing Services Agreement 

 
  

 
herein. If any public disclosure is required by law, the Parties will consult concerning the form of announcement prior to the public disclosure being made. 

 

	11.6	Marking. 

 The Disclosing Party agrees to use reasonable efforts to
summarize in writing the content of any oral disclosure or other non-tangible disclosure of Confidential Information within 30 days of the disclosure, but failure to provide this summary will not affect the nature of the Confidential Information
disclosed if the Confidential Information was identified as confidential or proprietary when disclosed orally or in any other non-tangible form. 
  

	11.7	Return of Confidential Information. 

 Upon the written request of the
Disclosing Party, the Recipient will promptly return the Confidential Information to the Disclosing Party or, if the Disclosing Party directs, destroy all Confidential Information disclosed in or reduced to tangible form including any copies thereof
and any summaries, compilations, analyses or other notes derived from the Confidential Information except for one copy which may be maintained by the Recipient for its records. The retained copy will remain subject to all confidentiality provisions
contained in this Agreement. 
  

	11.8	Remedies. 

 The Parties acknowledge that monetary damages may not be
sufficient to remedy a breach by either Party of this Agreement and agree that the non-breaching Party will be entitled to seek specific performance, injunctive and/or other equitable relief to prevent breaches of this Agreement and to specifically
enforce the provisions hereof in addition to any other remedies available at law or in equity. These remedies will not be the exclusive remedies for breach of this Agreement but will be in addition to any and all other remedies available at law or
in equity. 
 ARTICLE 12 

DISPUTE RESOLUTION 
  

	12.1	Commercial Disputes. 

 If any dispute arises out of this Agreement or any
Product Agreement (other than a dispute under Section 6.1(b) or a Technical Dispute, as defined herein), the Parties will first try to resolve it amicably. In that regard, any Party may send a notice of dispute to the other, and each Party will
appoint, within [...***...] Business Days from receipt of the notice of dispute, a single representative having full power and authority to resolve the dispute. The representatives
will meet as necessary in order to resolve the dispute. If the representatives fail to resolve the matter within [...***...] from their appointment, or if a Party fails to appoint a representative within the [...***...] Business Day
period set forth above, the dispute will immediately be referred to the Chief Operating Officer (or another officer as he/she may designate) of Patheon and the Chief Executive Officer of Client each Party who will meet and discuss as necessary to
try to resolve the dispute amicably. Should the Parties fail to reach a resolution under this Section 12.1, the dispute will be referred to a court of competent jurisdiction in accordance with Section 13.16. 

  
 ***Confidential
Treatment Requested 
 - 35 - 

 Master Manufacturing Services Agreement 

 
  

	12.2	Technical Dispute Resolution. 

 If a dispute arises (other than disputes
under Sections 6.1(b) or 12.1) between the Parties that is exclusively related to technical aspects of the manufacturing, packaging, labelling, quality control testing, handling, storage, or other activities under this Agreement (a
“Technical Dispute”), the Parties will make all reasonable efforts to resolve the dispute by amicable negotiations. In that regard, senior representatives of each Party will, as soon as possible and in any event no later than
[...***...] Business Days after a written request from either Party to the other, meet in good faith to resolve any Technical Dispute. If, despite this meeting, the Parties are unable to resolve a Technical Dispute within a reasonable time,
and in any event within [...***...] Business Days of the written request, the Technical Dispute will, at the request of either Party, be referred for determination to an expert in accordance with Exhibit A. If the Parties cannot agree that a
dispute is a Technical Dispute, Section 12.1 will prevail. For greater clarity, the Parties agree that the release of the Products for sale or distribution under the applicable marketing approval for the Products will not by itself indicate
compliance by Patheon with its obligations for the Manufacturing Services and further that nothing in this Agreement (including Exhibit A) will remove or limit the authority of the relevant qualified person (as specified by the Quality Agreement) to
determine whether the Products are to be released for sale or distribution. 

ARTICLE 13 

MISCELLANEOUS 
  

	13.1	Inventions. 

 (a) For the term of this Agreement, Client hereby grants to
Patheon a non-exclusive, paid-up, royalty-free, non-transferable license under Client’s Intellectual Property solely to the extent necessary for Patheon to perform the Manufacturing Services in accordance with this Agreement, and not for any
other purpose. 
 (b) All Inventions generated or derived by Patheon while performing the Manufacturing Services, to the extent relating
specifically to the development, manufacture, use or sale of any Product that is the subject of the Manufacturing Services, and all Client Intellectual Property, will be the exclusive property of Client. Patheon hereby assigns, and agrees to assign,
all of its right, title and interest in and to all such Inventions and Client Intellectual Property to Client and agrees to take all further acts reasonably required to evidence and/or perfect such assignment to Client, at Client’s expense.
Patheon will notify Client in writing, as promptly as practicable, of all Inventions and Client Intellectual Property made, created, discovered, generated or derived by Patheon in the course of performing the Manufacturing Services. Patheon may
retain one copy of records relating to Client Intellectual Property to the extent required under Applicable Laws. 
 (c) All Patheon
Intellectual Property will be the exclusive property of Patheon. Patheon hereby grants to Client a perpetual, irrevocable, non-exclusive, paid-up, royalty-free, transferable license, with the right to sublicense through multiple tiers, to use the
Patheon Intellectual Property used by Patheon to perform the Manufacturing Services to enable Client to manufacture the Product(s). 
 (d)
Each Party will be solely responsible for the costs of filing, prosecution, and maintenance of patents and patent applications on its own Inventions. 

  
 ***Confidential
Treatment Requested 
 - 36 - 

 Master Manufacturing Services Agreement 

 
  

	13.2	Intellectual Property. 

 All Client Intellectual Property will be owned by
Client and all Patheon Intellectual Property will be owned by Patheon. Neither Party has, nor will it acquire, any interest in any of the other Party’s Intellectual Property unless otherwise expressly agreed to in writing or expressly set forth
in this Agreement. Neither Party will use any Intellectual Property of the other Party, except as specifically authorized by the other Party or as required for the performance of its obligations under this Agreement. 

 

	13.3	Insurance. 

 Each Party will maintain commercial general liability
insurance, including blanket contractual liability insurance covering the obligations of that Party under this Agreement through the term of this Agreement and for a period of three years thereafter. This insurance will have policy limits of not
less than (i) $[...***...] for each occurrence for personal injury or property damage liability; and (ii) $[...***...] in the aggregate per annum for product and completed operations liability. If requested each Party will give
the other a certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the effective date, the expiration date, and the limits of liability. Each Party will further provide the other Party a minimum
of 30 days’ written notice of a cancellation of, or material change in, the insurance. If a Party is unable to maintain the insurance policies required under this Agreement through no fault of its own, then the Party will forthwith notify the
other Party in writing and the Parties will in good faith negotiate appropriate amendments to the insurance provision of this Agreement in order to provide adequate assurances. 

 

	13.4	Independent Contractors. 

 The Parties are independent contractors and this
Agreement and any Product Agreement will not be construed to create between Patheon and Client any other relationship such as, by way of example only, that of employer-employee, principal agent, joint-venturer, co-partners, or any similar
relationship, the existence of which is expressly denied by the Parties. 
  

	13.5	No Waiver. 

 Either Party’s failure to require the other Party to
comply with any provision of this Agreement or any Product Agreement will not be deemed a waiver of the provision or any other provision of this Agreement or any Product Agreement. 

 

	13.6	Assignment. 

 (a) Patheon may not assign this Agreement or any Product
Agreement or any of its associated rights or obligations, or subcontract any of its rights or obligations, hereunder without the written consent of Client, this consent not to be unreasonably withheld. But Patheon may arrange for subcontractors to
perform specific testing services arising under any Product Agreement without the consent of Client to the extent the subcontractors are specifically named and agreed in the Quality Agreement, provided that Patheon remains primarily liable to the
Client for performance by Patheon’s subcontractors. Further it is specifically agreed that Patheon may subcontract any part of the Services under a Product Agreement to any of its Affiliates to the extent the Affiliates are specifically named
and agreed in the applicable Product Agreement and in the Quality Agreement, provided that Patheon remains primarily liable to the Client for performance by Patheon’s Affiliates. 

(b) Subject to Section 8.2(e), Client may assign this Agreement or any Product Agreement or any of its associated rights or obligations
without approval from Patheon. Client will give Patheon prior 

  
 ***Confidential
Treatment Requested 
 - 37 - 

 Master Manufacturing Services Agreement 

 
  

 
written notice of any assignment, any assignee will covenant in writing with Patheon to be bound by the terms of this Agreement or the Product Agreement and Client will remain liable hereunder.
If Client only assigns a portion of this Agreement or a Product Agreement to a Third Party, the partial assignment will be subject to Patheon’s cost review of the assigned Products and Patheon may terminate this Agreement or the Product
Agreement or any assigned part thereof, on 18 months’ prior written notice to Client and the assignee if good faith discussions do not lead to agreement on amended Manufacturing Service fees within a reasonable time. But this time period will
automatically be extended by an additional three months if, at 18 months after the notice, Client is working in good-faith to secure, and/or obtain required approvals for, another supplier. 

(c) Despite the foregoing provisions of this Section 13.6, either Party may assign this Agreement or any Product Agreement to any of its
Affiliates or to a successor to or purchaser of all or substantially all of its business to which this Agreement relates, but the assignee must execute an agreement with the non-assigning Party whereby it agrees to be bound hereunder. 

 

	13.7	Force Majeure. 

 Neither Party will be liable for the failure to perform
its obligations under this Agreement or any Product Agreement if the failure is caused by an event beyond that Party’s reasonable control, including, but not limited to, strikes or other labor disturbances, lockouts, riots, quarantines,
communicable disease outbreaks, wars, acts of terrorism, fires, floods, storms, interruption of or delay in transportation, lack of or inability to obtain fuel, power or compliance with any order or regulation of any government entity acting within
colour of right (a “Force Majeure Event”). A Party claiming a right to excused performance under this Section 13.7 will immediately notify the other Party in writing of the extent of its inability to perform, which notice will
specify the event beyond its reasonable control that prevents the performance. Neither Party will be entitled to rely on a Force Majeure Event to relieve it from an obligation to pay money (including any interest for delayed payment) which would
otherwise be due and payable under this Agreement or any Product Agreement. If the performance of any obligation under this Agreement is delayed due to a Force Majeure Event for a continuous period of more than 60 days, the other Party may terminate
this Agreement without penalty upon written notice to the other Party under such event. All Annual Minimums will be suspended for the period of a Force Majeure Event but will be re-instated if the Force Majeure Event is cured. If this Agreement or
any Product Agreement is terminated due to a Force Majeure Event lasting longer than 60 days as set forth above, Client may request Patheon to reasonably assist in the transfer of the technology required to manufacture the Product to a third party
supplier designated by Client. If so requested, Patheon will promptly initiate and complete the technology transfer at Client’s cost. 
  

	13.8	Additional Product. 

 Additional Products may be added to, or existing
Products deleted from, any Product Agreement by amendments to the Product Agreement including Schedules A, B, C, and D as applicable. 
  

	13.9	Notices. 

 Unless otherwise agreed in a Product Agreement, any notice,
approval, instruction or other written communication required or permitted hereunder will be sufficient if made or given to the other Party by personal delivery, by telecopy, facsimile communication, or confirmed receipt email or by sending the same
by first class mail, postage prepaid to the respective addresses, telecopy or facsimile numbers or electronic mail addresses set forth below: 

  
 - 38 - 

 Master Manufacturing Services Agreement 

 
  

 If to Client: 

ACADIA Pharmaceuticals Inc. 

3611 Valley Centre Drive, Suite 300 

San Diego, CA 92130 
 Attention:
[...***...] 
 Telecopier No.: [...***...] 

Email address: [...***...] 

With a copy to: 
 ACADIA
Pharmaceuticals Inc. 
 3611 Valley Centre Drive, Suite 300 

San Diego, CA 92130 
 Attention:
[...***...] 
 Telecopier No.: [...***...] 

Email address: [...***...] 

If to Patheon: 
 Patheon
Pharmaceuticals Inc. 
 2110 East Galbraith Road 

Cincinnati, OH 45237-1625 

Attention: [...***...] 

Telecopier No.: [...***...] 

Email address: [...***...] 

With a copy to: 
 Patheon Inc.

 Canterbury Place 
 4815
Emperor Boulevard 
 Research Triangle Park, 

NC 27703 
 Attention:
[...***...] 
 Telecopier No.: [...***...] 

or to any other addresses, telecopy or facsimile numbers or electronic mail addresses given to the other Party in accordance with the terms of this
Section 13.9. Notices or written communications made or given by personal delivery, telecopy, facsimile, or electronic mail will be deemed to have been sufficiently made or given when sent (receipt acknowledged), or if mailed, five days after
being deposited in the United States, Canada, or European Union mail, postage prepaid or upon receipt, whichever is sooner, or one Business Day after being sent by overnight courier. 

  
 ***Confidential
Treatment Requested 
 - 39 - 

 Master Manufacturing Services Agreement 

 
  

	13.10	Severability. 

 If any provision of this Agreement or any Product Agreement
is determined by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, that determination will not impair or affect the validity, legality, or enforceability of the remaining provisions, because each provision is
separate, severable, and distinct. 
  

	13.11	Entire Agreement. 

 This Agreement, and all Schedules hereto, together with
the applicable Product Agreement and Quality Agreement, constitutes the full, complete, final and integrated agreement between the Parties relating to the subject matter hereof and supersedes all previous written or oral negotiations, commitments,
agreements, transactions, or understandings concerning the subject matter hereof. Any modification, amendment, or supplement to this Agreement or any Product Agreement must be in writing and signed by authorized representatives of the Parties. In
case of conflict, the prevailing order of documents will be this Agreement, the Product Agreement, and the Quality Agreement. 
  

	13.12	Other Terms. 

 No terms, provisions or conditions of any purchase order or
other business form or written authorization used by Client or Patheon will have any effect on the rights, duties, or obligations of the Parties under or otherwise modify this Agreement or any Product Agreement, regardless of any failure of Client
or Patheon to object to the terms, provisions, or conditions unless the document specifically refers to this Agreement or the applicable Product Agreement and is signed by the Parties. 

 

	13.13	No Third Party Benefit or Right. 

 For greater clarity, nothing in this
Agreement or any Product Agreement will confer or be construed as conferring on any third party any benefit or the right to enforce any express or implied term of this Agreement or any Product Agreement. 

 

	13.14	Execution in Counterparts. 

 This Agreement and any Product Agreement may
be executed in two or more counterparts, by original or facsimile signature, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 

 

	13.15	Use of Client Name. 

 Patheon will not make any use of Client’s name,
trademarks or logo or any variations thereof, alone or with any other word or words, without the prior written consent of Client, which consent will not be unreasonably withheld. Despite this, Client agrees that Patheon may include
Client’s name and logo in customer lists or related marketing and promotional material for the purpose of identifying users of Patheon’s Manufacturing Services.
  

	13.16	Governing Law. 

 This Agreement and any Product Agreement will be construed
and enforced in accordance with the laws of the State of New York and the laws of the United States of America applicable therein and subject to the exclusive jurisdiction of the courts thereof. The UN Convention on Contracts for the International
Sale of Goods will not apply to this Agreement or any Product Agreement. 

  
 - 40 - 

 Master Manufacturing Services Agreement 

 
  

 IN WITNESS WHEREOF, the duly authorized representatives of the Parties have executed this
Agreement as of the date first written above. 
  

			
	PATHEON PHARMACEUTICALS INC.
		
	By:	 	/s/ Francis P. McCune
	Name:	 	Francis P. McCune
	Title:	 	Secretary
	
	ACADIA PHARMACEUTICALS INC.
		
	By:	 	/s/ Steve Davis
	Name:	 	Steve Davis
	Title:	 	Interim CEO

  
 - 41 - 

 Master Manufacturing Services Agreement 

 
 APPENDIX 1 

FORM OF PRODUCT AGREEMENT 

(Includes Schedules A to D) 

PRODUCT AGREEMENT 

This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated
August 3, 2015 between Patheon Pharmaceuticals Inc., and ACADIA Pharmaceuticals Inc. (the “Master Agreement”), and is entered into [insert effective date] (the “Effective Date”), between
Patheon Pharmaceuticals Inc., [or applicable Patheon Affiliate], a corporation existing under the laws of the State of Delaware [or applicable founding jurisdiction for Patheon Affiliate], having a principal place of business at 2110
East Galbraith Road, Cincinnati, OH 45237-1625 [or Patheon Affiliate address] (“Patheon”) and [insert Client name, legal entity, founding jurisdiction and address] (“Client”). 

The terms and conditions of the Master Agreement are incorporated herein except to the extent this Product Agreement expressly references the
specific provision in the Master Agreement to be modified by this Product Agreement. All capitalized terms that are used but not defined in this Product Agreement will have the respective meanings given to them in the Master Agreement. 

The Schedules to this Product Agreement are incorporated into and will be construed in accordance with the terms of this Product Agreement.

  

	 	1.	Product List and Specifications (See Schedule A attached hereto) 

  

	 	2.	Minimum Order Quantity, Annual Volume, and Price (See Schedule B attached hereto) 

  

	 	3.	Annual Stability Testing and Validation Activities (if applicable) (See Schedule C attached hereto) 

  

	 	4.	Active Materials, Active Materials Credit Value, and Maximum Credit Value (See Schedule D attached hereto) 

  

	 	5.	Yearly Forecasted Volume: (insert for sterile products if applicable under Section 4.2.1 of the Master Agreement) 

  

	 	6.	Territory: (insert the description of the Territory here) 

  

	 	7.	Manufacturing Site: (insert address of Patheon Manufacturing Site where the Manufacturing Services will be performed) 

  

	 	8.	Governing Law: (if applicable under Section 13.16 of the Master Agreement) 

  

	 	9.	Inflation Index: (if applicable under Section 4.2(a) of the Master Agreement for Products manufactured outside of the Unites States or Puerto Rico) 

 

	 	10.	Currency: (if applicable under Section 1.4 of the Master Agreement) 

 Master Manufacturing Services Agreement 

 
  

	 	11.	Initial Set Exchange Rate: (if applicable under Section 4.2(d) of the Master Agreement) 

  

	 	12.	Initial Product Term: (if applicable under Section 8.1 of the Master Agreement) 

  

	 	13.	Notices: (if applicable under Section 13.9 of the Master Agreement) 

  

	 	14.	Other Modifications to the Master Agreement: (if applicable under Section 1.2 of the Master Agreement) 

  

 
 IN WITNESS
WHEREOF, the duly authorized representatives of the Parties have executed this Product Agreement as of the Effective Date set forth above. 
  

			
	PATHEON PHARMACEUTICALS INC. [or applicable Patheon Affiliate]
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	ACADIA PHARMACEUTICALS INC. [or applicable Client Affiliate]
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 - 2 - 

 Master Manufacturing Services Agreement 

 
  

 SCHEDULE A 

PRODUCT LIST AND SPECIFICATIONS 

Product List 
 [insert product list] 

Specifications 
 Prior to the start of commercial
manufacturing of Product under this Agreement Client will give Patheon the originally executed copies of the Specifications as approved by the applicable Regulatory Authority or as most recently filed with such Regulatory Authority. If the
Specifications received are subsequently amended, then Client will give Patheon the revised and originally executed copies of the revised Specifications. Upon acceptance of the revised Specifications, Patheon will give Client a signed and dated
receipt indicating Patheon’s receipt of the revised Specifications. 

 Master Manufacturing Services Agreement 

 
  

 SCHEDULE B 

MINIMUM ORDER QUANTITY, ANNUAL VOLUME, AND PRICE 
  

							
		  	 [Insert Price Table]
	  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	

 Manufacturing Assumptions: 

Packaging Assumptions: 
 Testing
Assumptions: 
 Costs Included in Unit Pricing 

[...***...] 

***Confidential Treatment Requested 

  

 Master Manufacturing Services Agreement 

 
  

 Costs Not Included in Unit Pricing 

[...***...] 

  
 ***Confidential
Treatment Requested 
 - 2 - 

 Master Manufacturing Services Agreement 

 
  

 [...***...] 

 

  
 ***Confidential
Treatment Requested 
 - 3 - 

 Master Manufacturing Services Agreement 

 
  

 SCHEDULE C 

ANNUAL STABILITY TESTING 
 Patheon
and Client will agree in writing on any stability testing to be performed by Patheon on the Products. This agreement will specify the commercial and Product stability protocols applicable to the stability testing and the fees payable by Client for
this testing. 
 [NTD: Schedule C should clearly indicate when and/or under what conditions Patheon’s responsibility to perform stability testing
will end] 

 Master Manufacturing Services Agreement 

 
  

 SCHEDULE D 

ACTIVE MATERIALS 
  

			
	Active Materials	  	Supplier
	 ●
	  	●
	 ●
	  	●

 ACTIVE MATERIALS CREDIT VALUE 

The Active Materials Credit Value will be as follows: 
  

					
	PRODUCT	  	ACTIVE MATERIALS	  	 ACTIVE
MATERIALS
 CREDIT VALUE

	 	  	 	  	Client’s actual cost for Active Materials not to exceed
$         per kilogram
		  		  	

 MAXIMUM CREDIT VALUE 

Patheon’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will
not exceed, in the aggregate, the maximum credit value set forth below: 
  

			
	PRODUCT	  	MAXIMUM CREDIT VALUE
	 	  	[...***...]
	 	  	 

 [End of Product Agreement] 

  
 ***Confidential
Treatment Requested 

 Master Manufacturing Services Agreement 

 
  

 EXHIBIT A 

TECHNICAL DISPUTE RESOLUTION 

Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 will be resolved in the following manner: 

1. Appointment of Expert. Within [...***...] Business Days after a Party requests under Section 12.2 that an expert be appointed to
resolve a Technical Dispute, the Parties will jointly appoint a mutually acceptable expert with experience and expertise in the subject matter of the dispute. If the Parties are unable to so agree within the [...***...] Business Day period, or
in the event of disclosure of a conflict by an expert under Paragraph 2 hereof which results in the Parties not confirming the appointment of the expert, then an expert (willing to act in that capacity hereunder) will be appointed by an experienced
arbitrator on the roster of the American Arbitration Association. 
 2. Conflicts of
Interest. Any person appointed as an expert will be entitled to act and continue to act as an expert even if at the time of his appointment or at any time before he gives his determination, he has or may have some interest or duty which
conflicts or may conflict with his appointment if before accepting the appointment (or as soon as practicable after he becomes aware of the conflict or potential conflict) he fully discloses the interest or duty and the Parties will, after the
disclosure, have confirmed his appointment. 
 3. Not Arbitrator. No expert will be deemed to be an arbitrator and the provisions of the
American Arbitration Act or of any other applicable statute (foreign or domestic) and the law relating to arbitration will not apply to the expert or the expert’s determination or the procedure by which the expert reaches his determination
under this Exhibit A. 
 4. Procedure. Where an expert is appointed: 
  

	 	(a)	Timing. The expert will be so appointed on condition that (i) he promptly fixes a reasonable time and place for receiving representations, submissions or information from the Parties and that he issues the
authorizations to the Parties and any relevant third party for the proper conduct of his determination and any hearing and (ii) he renders his decision (with full reasons) within [...***...] Business Days (or another other date as the
Parties and the expert may agree) after receipt of all information requested by him under Paragraph 4(b) hereof. 

  

	 	(b)	Disclosure of Evidence. The Parties undertake one to the other to give to any expert all the evidence and information within their respective possession or control as the expert may reasonably consider necessary
for determining the matter before him which they will disclose promptly and in any event within [...***...] Business Days of a written request from the relevant expert to do so. 

 

	 	(c)	Advisors. Each Party may appoint any counsel, consultants and advisors as it feels appropriate to assist the expert in his determination and so as to present their respective cases so that at all times the
Parties will co-operate and seek to narrow and limit the issues to be determined. 

  

	 	(d)	 Appointment of New Expert. If within the time specified in Paragraph 4(a) above the expert will not have rendered a decision in accordance with
his appointment, a new expert may (at the request of either Party) be appointed and the appointment of the existing expert will thereupon cease for the purposes of determining the matter at issue between the Parties save this if the existing expert
renders his decision with full reasons 

  
 ***Confidential
Treatment Requested 

 Master Manufacturing Services Agreement 

 
  

	 	
prior to the appointment of the new expert, then this decision will have effect and the proposed appointment of the new expert will be withdrawn. 

 

	 	(e)	Final and Binding. The determination of the expert will, except for fraud or manifest error, be final and binding upon the Parties. 

 

	 	(f)	Costs. Each Party will bear its own costs for any matter referred to an expert hereunder and, in the absence of express provision in the Agreement to the contrary, the costs and expenses of the expert will be
shared equally by the Parties. 

 For greater certainty, the release of the Products for sale or distribution under the applicable marketing
approval for the Products will not by itself indicate compliance by Patheon with its obligations for the Manufacturing Services and further that nothing in this Agreement (including this Exhibit A) will remove or limit the authority of the relevant
qualified person (as specified by the Quality Agreement) to determine whether the Products are to be released for sale or distribution. 

  
 - 2 - 

 Master Manufacturing Services Agreement 

 
  

 EXHIBIT B 

MONTHLY ACTIVE MATERIALS INVENTORY REPORT 
  

			
	TO:	  	ACADIA PHARMACEUTICALS INC.
		
	FROM:	  	PATHEON PHARMACEUTICALS INC. [or applicable Patheon Affiliate]
		
	RE:	  	Active Materials monthly inventory report under Section 2.2(a) of the Master Manufacturing Services Agreement dated August 3, 2015 (the “Agreement”)

  
  

 

									
	Reporting month:	  	  
	 		  		  	
					
	Active Materials on hand at beginning of month:	  	  
	 	kg	  	(A)	  	
					
	Active Materials on hand at end of month:	  	  
	 	kg	  	(B)	  	
					
	Quantity Received during month:	  	  
	 	kg	  	(C)	  	
					
	 Quantity Dispensed1 during month:

(A + C – B)
	  	  
	 	kg	  		  	
					
	Quantity Converted during month:	  	  
	 	kg	  		  	
	 (total Active Materials in Products produced

and not rejected, recalled or returned)
	  		 		  		  	

 Capitalized terms used in this report have the meanings given to the terms in the Agreement. 

 

							
	PATHEON PHARMACEUTICALS INC.	 		 	DATE:                                     
                               
	[or applicable Patheon Affiliate]	 		 	

							
				
	Per:	 	  
	 		 	
	Name:	 		 		 	
	Title:	 		 		 	

  

	1 	Excludes any (i) Active Materials that must be retained by Patheon as samples, (ii) Active Materials contained in Product that must be retained as samples, (iii) Active Materials used in testing (if applicable), and
(iv) Active Materials received or consumed in technical transfer activities or development activities, including, without limitation, any regulatory, stability, validation, or test Batches manufactured during the month. 

  

 Master Manufacturing Services Agreement 

 
  

 EXHIBIT C 

REPORT OF ANNUAL ACTIVE MATERIALS INVENTORY RECONCILIATION 

AND CALCULATION OF ACTUAL ANNUAL YIELD 
  

			
	TO:	  	ACADIA PHARMACEUTICALS INC.
		
	FROM:	  	PATHEON PHARMACEUTICALS INC. [or applicable Patheon Affiliate]
		
	RE:	  	Active Materials annual inventory reconciliation report and calculation of Actual Annual Yield under Section 2.2(a) of the Master Manufacturing Services Agreement dated August 3, 2015 (the “Agreement”)

  
  

 

											
	Reporting Year ending:	 		 	  
	 		  		  	
						
	Active Materials on hand at beginning of Year:	 		 	  
	 	kg	  	(A)	  	
						
	Active Materials on hand at end of Year:	 		 	  
	 	kg	  	(B)	  	
						
	Quantity Received during Year:	 		 	  
	 	kg	  	(C)	  	
						
	 Quantity Dispensed2 during Year:

(A + C - B)
	 		 	  
	 	kg	  	(D)	  	
						
	Quantity Converted during Year:	 		 	  
	 	kg	  	(E)	  	
	 (total Active Materials in Products produced

and not rejected, recalled or returned)
	 		 		 		  		  	
						
	Active Materials Credit Value:	 	$	 	  
	 	/ kg	  	(F)	  	
						
	Target Yield:	 		 	  
	 	%	  	(G)	  	
						
	Actual Annual Yield:	 		 	  
	 	%	  	(H)	  	

  

	2	Excludes any (i) Active Materials that must be retained by Patheon as samples, (ii) Active Materials contained in Product that must be retained as samples, (iii)
Active Materials used in testing (if applicable), and (iv) Active Materials received or consumed in technical transfer activities or development activities, including, without limitation, any regulatory, stability, validation, or test Batches
manufactured during the Year. 

 Master Manufacturing Services Agreement 

 
  

					
	((E / D) * 100)	  		  	
			
	Shortfall:	  	        $                             
           	  	(I)

					
	(((G – [...***...]) - H) / 100) * F * D	  	 (if a negative number, insert zero)
	  	

 Based on the foregoing reimbursement calculation Patheon will reimburse Client the amount of
$        . 
 Capitalized terms used in this report have the meanings given to the terms in the Agreement.

 DATE:                      

 

			
	PATHEON PHARMACEUTICALS INC.
	[or applicable Patheon Affiliate]
		
	Per:	 	  

	Name:	 	
	Title:	 	

  
 ***Confidential
Treatment Requested 
 - 2 - 

 Master Manufacturing Services Agreement 

 
  

 EXHIBIT D 

EXAMPLE OF PRICE ADJUSTMENT DUE TO CURRENCY FLUCTUATION 

Section 4.2(d) 
  

 
 Time period: 10/01/11 to 09/30/12. 

Average (365 days): 0.998 – “Set Exchange Rate” 

 

			
		 	  

    SAMPLE EXCHANGE CALCULATION 

 

							
		 	Initial Exchange Rate:	    	1.000	  	 CAD/USD

		 	Set Exchange Rate:	    	0.998	  	 CAD/USD

				
		 	Initial Price:	    		  	3.59
		 	Revised Price (FX):	    		  	3.70 (Material price and PPI adjustments)
				
		 	Calculation:	    		  	
		
		 	 [Revised Price (After FX)] = [Revised Price (Before FX)] × [Initial Exchange Rate] / [Set Exchange Rate]

			
		 		    	= 3.70 × [1.000 / 0.998]
			
		 		    	= 3.71

  
 - 2 - 

 ***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 

PRODUCT AGREEMENT 

This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated
August 3, 2015 between Patheon Pharmaceuticals Inc., and ACADIA Pharmaceuticals Inc. (the “Master Agreement”), and is entered into as of August 3, 2015 (the “Effective Date”), between Patheon
Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, having a principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237-1625 (“Patheon”) and ACADIA Pharmaceuticals Inc., a
corporation existing under the laws of the State of Delaware, having a principal place of business at 3611 Valley Centre Drive, Ste. 300, San Diego, CA 92130 (“Client”). 

The terms and conditions of the Master Agreement are incorporated herein except to the extent this Product Agreement expressly references the
specific provision in the Master Agreement to be modified by this Product Agreement. All capitalized terms that are used but not defined in this Product Agreement will have the respective meanings given to them in the Master Agreement. 

The Schedules to this Product Agreement are incorporated into and will be construed in accordance with the terms of this Product Agreement.

  

	 	1.	Product List and Specifications (See Schedule A attached hereto) 

  

	 	2.	Minimum Order Quantity, Annual Volume, and Price (See Schedule B attached hereto) 

  

	 	3.	Annual Stability Testing (See Schedule C attached hereto) 

  

	 	4.	Active Materials, Active Materials Credit Value, and Maximum Credit Value (See Schedule D attached hereto) 

  

	 	5.	Yearly Forecasted Volume: Not applicable 

  

	 	6.	Territory: The United States 

  

	 	7.	Manufacturing Site: Patheon Pharmaceuticals Inc., 2110 East Galbraith Road, Cincinnati, OH 45237-1625. 

  

	 	8.	Governing Law: Per Section 13.16 of the Master Agreement 

  

	 	9.	Inflation Index: Per Section 4.2(a) of the Master Agreement 

  

	 	10.	Currency: Per Section 1.4 of the Master Agreement 

  

	 	11.	Initial Set Exchange Rate: Not applicable 

  

	 	12.	Initial Product Term: From the Effective Date through December 31, 2020. 

  

	 	13.	Notices: Per Section 13.9 of the Master Agreement 

  

	 	14.	Other Modifications to the Master Agreement: Not applicable 

 IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this Product
Agreement as of the Effective Date set forth above. 
  

			
	PATHEON PHARMACEUTICALS INC.
		
	By:	 	/s/ Francis P. McCune
	Name:	 	Francis P. McCune
	Title:	 	Secretary
	
	ACADIA PHARMACEUTICALS INC.
		
	By:	 	/s/ Steve Davis
	Name:	 	Steve Davis
	Title:	 	Interim CEO

 SCHEDULE A 

PRODUCT LIST AND SPECIFICATIONS 

Product List 
 Pimavanserin Tablets 17 mg strength
(the “Product”) 
 Specifications 

Prior to the start of commercial manufacturing of the Product under this Agreement Client will give Patheon the originally executed copies of the
Specifications as approved by the applicable Regulatory Authority or as most recently filed with such Regulatory Authority. If the Specifications received are subsequently amended, then Client will give Patheon the revised and originally executed
copies of the revised Specifications. Upon acceptance of the revised Specifications, Patheon will give Client a signed and dated receipt indicating Patheon’s acceptance of the revised Specifications. 

 SCHEDULE B 

MINIMUM ORDER QUANTITY, ANNUAL VOLUME AND PRICE 

Annual Volume Forecasts 
 Patheon is presenting pricing
based on the following volume. 
  

			
	Product	  	# of Batches [...***...]
	
Pimavanserin Tablets
	  	[...***...]

 Pricing Table 
 Pricing
includes the cost of labor, overhead, raw materials, packaging components and QC testing and such additional items noted as being included in the price as described below. 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Costs Included in Unit Pricing 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Costs Not Included in Unit Pricing 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Key Technical Assumptions 

Below are listed the main assumptions that were utilized by Patheon for quoting this Product. Should any of the assumptions change, then the prices will be
revised accordingly as agreed by the Parties. 
 Manufacturing Assumptions 
  

	 	•	 	The manufacturing process at Patheon will follow the master Batch Product record approved by the Parties. 

  

	 	•	 	The core tablet weights and manufacturing batch sizes for each strength are summarized in the following table. 

[...***...] 

 

	 	•	 	The following manufacturing equipment train is used for the Product. 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Packaging Assumptions 

The Product will be packaged into the configurations listed in the tables below. 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Testing Assumptions 
  

	 	•	 	Testing for raw materials, excipients, packaging components and finished Product are based on information provided by Client. 

  

	 	•	 	Full release testing of API is included. 

  

	 	•	 	It is assumed that QC test methods are fully validated and robust. 

  

	 	•	 	Micro testing has been included on the finished Product. 

  

	 	•	 	Testing labor may be subject to change after the final agreement on testing specifications and requirements. 

Supply Chain Assumptions 
  

	 	•	 	The quoted raw materials and packaging components (other than Client-Supplied Components) are assumed to be supplied from standard Patheon suppliers. This will need to be reviewed upon the detailed specifications of
these materials. Patheon will procure components (raw materials and primary packaging materials) for the manufacture of the Product from Patheon qualified suppliers. Should Client require Patheon to source any materials from specified suppliers
other than Patheon qualified suppliers or those otherwise agreed upon in the Master Agreement, as applicable, then these suppliers will remain under the quality audit control of Client unless it is agreed that Patheon will take on this
responsibility. Components and excipients to be supplied by Patheon in accordance with Client’s specifications. Patheon will issue formal Patheon specifications for each component following Client component requirements. Each lot of incoming
components will be sampled and tested according to the agreed specifications. If different component specifications for primary packaging are required, these will be subject to a further evaluation and assessment by Patheon. 

 SCHEDULE C 

ANNUAL STABILITY TESTING 
 Patheon
and Client will agree in writing on any stability testing to be performed by Patheon on the Products. This agreement will specify the commercial and Product stability protocols applicable to the stability testing and the fees payable by Client for
this testing. Release testing will be used for time zero testing as long as batches are placed on stability within [...***...] days of completion of release testing. Patheon will be responsible for retest of time zero if delay of placing
batches are due to Patheon. Client will be responsible for $[...***...] per sample for any batch delayed more than [...***...] days from release testing due to Client. 

[...***...] 

  
 ***Confidential
Treatment Requested 

 SCHEDULE D 

ACTIVE MATERIALS 
  

			
	Active Materials	  	
Supplier
  

	
Pimavanserin tartrate
	  	BASF Pharma (Evionnaz) SA and/or its affiliates

 ACTIVE MATERIALS CREDIT VALUE 

The Active Materials Credit Value will be as follows: 
  

					
	PRODUCT	  	ACTIVE MATERIALS  	  	 ACTIVE
MATERIALS
 CREDIT VALUE

	Pimavanserin tablets 17 mg strength	  	Pimavanserin tartrate	  	Client’s actual cost for Active Materials not to exceed $[...***...] per kilogram

 MAXIMUM CREDIT VALUE 

Patheon’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for Product in a Year will not exceed, in
the aggregate, the maximum credit value set forth below: 
  

			
	PRODUCT	  	MAXIMUM CREDIT VALUE
	Pimavanserin tablets 17 mg strength	  	[...***...]

  
 ***Confidential
Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]